



ISSUE 03 • AUG 2025

PATHFOCUS

Department of Pathology, Molecular & Cell-Based Medicine



DEPARTMENT OF PATHOLOGY NEWSLETTER

Features

03 Molecular Microbiology Laboratory:
Advancing Infectious Disease Diagnostics
During the Pandemic and Beyond

04 Spotlight On: Hematopathology
Division

05 Spotlight On: Transfusion Medicine
Services

06 Grossing Hubs and Our Pathologists'
Assistants - The Core of Surgical Pathology

07 Departmental Activities - In Photos

MESSAGE FROM THE CHAIR



It is with great pride and enthusiasm that I welcome you to the latest issue of PATHFocus, a publication that continues to reflect the extraordinary energy, innovation, and excellence of our Department of Pathology, Molecular and Cell-Based Medicine. Since our last issue, we have experienced remarkable momentum across all fronts, including clinical services, education, and research, driven by your dedication and commitment. Among our most exciting recent accomplishments, our residency program has been top ranked in New York State by the newly released Doximity "Residency Navigator," surpassing Columbia, Cornell, and NYU. This recognition reflects the excellence and innovation of our educational programs, the quality of our faculty, the rigor of our training, and the collaborative spirit that defines our department. We continue to distinguish ourselves globally as the only pathology department operating fully with digital pathology, enabling unparalleled diagnostic accuracy, workflow efficiency, and educational opportunities. Expansion is evident across key subspecialties, including Transplant Pathology, with a new contract in place with LiveOnNY, as well as cutting-edge molecular microbiology testing with a broadened panel of syndromic assays. This issue of PATHFocus highlights major achievements from our Hematopathology and Transfusion Medicine divisions in the "Spotlight On" section, underlining the caliber and impact of their work. We are also proud to introduce a new feature: "In-Depth Look," which in this issue centers on the critical roles of our Pathologists' Assistants (PAs) through the Mount Sinai Health System. All of these achievements underscore the remarkable trajectory of our department, reflecting the collective vision, creativity, forward-thinking, and resourcefulness of our faculty. I remain deeply honored to represent this community of exceptional individuals, and I thank you all for your continued dedication, support, and inspiration.

A handwritten signature in black ink, reading "Carlos Cordon-Cardo".

Carlos Cordon-Cardo, MD, PhD

Chairman, Department of Pathology, Molecular
and Cell-Based Medicine



THE MOLECULAR MICROBIOLOGY LABORATORY: ADVANCING INFECTIOUS DISEASE DIAGNOSTICS AT MOUNT SINAI

By Alberto Paniz Mondolfi, MD, PhD

When we founded the Molecular Microbiology Laboratory (MML) at Mount Sinai in 2020, we did so with a clear mission: to bring cutting-edge, clinically relevant molecular diagnostics to the frontlines of patient care. From day one, our philosophy has centered on scientific rigor, innovation, and urgency—because in infectious disease diagnostics, time and accuracy save lives.

One of our most defining contributions has been the development and implementation of Laboratory Developed Tests (LDTs). These are more than just technical achievements—they represent a proactive response to real-world clinical needs. From the rapid deployment of saliva-based SARS-CoV-2 PCR assays during the pandemic, which supported New York City's safe reopening, to our early response to the 2022 Monkeypox outbreak with in-house RT-PCR testing, our team has consistently delivered timely solutions when they were most needed.

To date, we have developed over fifteen New York State-approved LDTs, spanning a wide range of pathogens including *Trypanosoma cruzi*, *Leishmania* spp., *Acanthamoeba*, *Plasmodium*, *Babesia*, Human T-lymphotropic virus types 1/2 (HTLV-1/2) and high-risk HPV genotyping. These tools now serve as critical components in our diagnostic arsenal, allowing us to identify rare, neglected, and emerging infections that often go undetected in conventional settings.

Mount Sinai Seeks to Expand School Virus Testing Program


The health system, which is preparing to open a new laboratory that could process 100,000 tests a day, wants to take its program to public schools this fall.

Give this article



Students at KIPP Infinity Middle School in West Harlem with tubes for collecting saliva, part of a coronavirus testing pilot program. "It's way better than just sticking a stick up your nose," one student said. Mount Sinai Health System

Photo: Article from *The New York Times*, 2025




At the core of our success is a multidisciplinary team—technologists, postdocs, administrative staff—whose passion and dedication drive everything we do. As Director, I am proud to say that our work does not stop at diagnostics. We are deeply involved in basic research, collaborating with colleagues across Mount Sinai to enhance pathogen detection in FFPE tissues and decipher mechanisms of disease at the molecular level. We've published over 100 peer-reviewed papers, highlighting our lab's impactful contributions to molecular diagnostics and infectious disease research.

In partnership with Mount Sinai's Pathogen Surveillance Program, our lab is advancing outbreak response and diagnostic preparedness. Looking ahead, we are developing the Center for Advanced Microbial Diagnostics (CAMD)—a centralized hub for cutting-edge molecular testing, sequencing, and pathogen discovery.

Moving forward, we are also pioneering the integration of next-generation sequencing into the clinical pipeline under a framework of diagnostic stewardship. By marrying advanced molecular technologies with thoughtful clinical application, we're not just improving outcomes—we're reshaping how infectious diseases are approached in modern medicine.

Our lab is more than a testing facility—it is a living example of how translational science can meet urgent clinical demands. Every assay we build, every result we validate, and every discovery we publish reflects our unwavering commitment to improving patient care through innovation.

SPOTLIGHT ON: HEMATOPATHOLOGY DIVISION



Hemepath Faculty from left to right: Dr. Christian Salib, Dr. Shafinaz Hussein, Dr. Bruce Petersen, Dr. Amy Duffield, Dr. Alina Dulau and Dr. Matthew Shapiro

By Dr. Shafinaz Hussein

The Hematopathology Division at Mount Sinai Hospital has undergone exciting new changes in the past few years. The section consists of a dynamic group of highly talented and accomplished hematopathologists, laboratory scientists, technologists, and administrative staff.

Several of our outstanding and experienced faculty have been at Mount Sinai Hospital for years and are well known to the department, including Drs. Bruce Petersen, Shafinaz Hussein and Christian Salib. Within the past two years, the Hematopathology Division has also welcomed four new faculty members: Drs. Matthew Shapiro, Dalia Azim, Alina Dulau, and Amy Duffield. Dr. Shapiro, a previous Pathology resident at Mount Sinai and a graduate of our Hematopathology fellowship program, divides his time between the Hematology and Hematopathology sections and more recently has been appointed as director of the bone marrow aspirate lab. In this role he will be optimizing the workflow and quality of the bone marrow aspirates. Dr. Azim was previously at New York University and Cairo Diagnostics, and is board certified not only in Hematopathology but also in Molecular Diagnostics. Dr. Dulau comes to us from the National Institutes of Health, and has extensive research experience, with a special interest in myeloid malignancies and bone marrow failure. As the Director of Hematopathology, Dr. Duffield is an internationally recognized hematopathologist who was previously on the faculty at Johns Hopkins Hospital and Memorial Sloan Kettering Cancer Center. Her expertise in acute lymphoblastic leukemia and non-neoplastic lymph node pathology is an acclaimed welcome, both to the division and Department of Pathology, Molecular and Cell-Based Medicine as a whole.

An integral part of the Hematopathology division, the Flow Cytometry Laboratory has undergone exciting new developments in recent years. Under the leadership of Drs. Wei Cai and Hemant Joshi, and with the support of Drs. Hussein and Duffield, the lab has implemented advanced multiparameter flow cytometry assays for immunophenotyping, streamlined the workflow to ensure efficient and rapid turn-around time, and established forums for laboratory technologist and trainee education. In 2024, the lab processed over 26,000 lymphocyte subset samples, approximately 7300 leukemia / lymphoma samples and nearly 900 samples for CD34 counts, with continued increase in volume anticipated for 2025.

Efforts are also underway to expand the test menu to provide enhanced diagnostic services that further support our oncology colleagues, including implementation of the multiple myeloma measurable / minimal residual disease (MRD) flow cytometry assay that was approved by the New York State Department of Health in 2024. The lab's commitment to excellence is further demonstrated by a 100% pass rate on CAP proficiency tests and zero deficiencies reported in both CAP and New York State inspections performed in 2024.

In the realm of digital pathology, the Division of Hematopathology has begun implementing digitization of bone marrow aspirate smear slides using the recently FDA-cleared Scopio X100HT imaging system with artificial intelligence support. This innovative initiative, which was spearheaded by Dr. Salib, marks a significant milestone, continuing our department's preeminence in image analysis and digital pathology within diagnostic practices. The integration of this technology will enhance diagnostic accuracy, improve turnaround times, and foster new collaborative opportunities in clinical practice and research within the Mount Sinai Health System. The Hematopathology Fellowship program, under the direction of Dr. Hussein and with the assistance of Drs. Salib and Azim, and Scott Goldfarb, has also seen tremendous growth, including the recent addition of a second ACGME approved 1-year fellowship position. The division manages a large volume of clinical cases, and the diversity and case complexity at MSH fuels the faculty's enthusiasm, paving the way for opportunities for teaching, mentoring, and scholarly pursuits. Additionally, observerships within the Hematopathology division are frequently requested by trainees and medical students from both the Icahn School of Medicine and external institutions. Over the past two years, under the mentorship of the Hematopathology faculty members, our residents and fellows have been selected for platform and poster presentations at several national and international conferences, including the New York Hematopathology Group Meeting, Atlantic Regional Hematopathology Society, Society for Hematopathology, and European Association for Hematopathology. Our faculty takes immense pride in the growth and accomplishments of the fellows and residents during their time in Hematopathology.



The Flow Lab Team headed by Dr. Joshi Hemant and Dr. Wei Cai (2nd and 3rd from the bottom left)

The accomplishments of recent years are attributable to the efforts of the division's entire team of dedicated hematopathologists, skilled laboratory scientists and technologists, and supportive administrative staff. A cornerstone of the division's success is its commitment to integrating advanced diagnostic methods / tools to provide the best patient care and fostering collaborative relationships. The Division of Hematopathology has flourished into a division that stands out for its excellence in diagnostics, education and research, and we are looking forward to continuing progress and diagnostic excellence.

SPOTLIGHT ON: TRANSFUSION MEDICINE SERVICES

By Dr. Camelia Iancu-Rubin

Transfusion Medicine is a comprehensive branch in the Department of Pathology, Molecular and Cell-Based Medicine that plays a crucial role within the Mount Sinai Health System by providing necessary and sometimes life-saving blood transfusions, therapeutic apheresis procedures and cellular therapies, and ensure the safety and efficacy of these treatments. Transfusion Medicine faculty oversees **Blood Bank** services at all sites across Mount Sinai Health System and the **Apheresis and Cellular Therapy** services at Mount Sinai Hospital. Our faculty members work alongside medical laboratory scientists, nurses, clinicians, and other health care providers across all medical specialties to provide consultative services to help facilitate safe, appropriate, and evidence-based transfusion practices. Transfusion Medicine services follow strict regulatory standards and undergo regular inspections to ensure patients and products safety and quality compliance. Our laboratories and facilities are registered with the U.S. Food and Drug Administration, licensed by the New York State Department of Health and accredited by the Association for the Advancement of Blood & Biotherapies, the College of American Pathologists, and the Foundation for the Accreditation of Cellular Therapy.

The Blood Banks support both the inpatient and outpatient transfusion services throughout the Mount Sinai Health System by providing over 70,000 units of blood, plasma, platelets, and derivatives for transfusion. Blood transfusions are administered to patients for surgical, hemorrhagic, obstetric, oncologic, or other medical indications. Blood bank physicians provide clinical, quality, and regulatory oversight, pertaining to product storage, pre-transfusion testing, transfusion appropriateness, and the identification, classification, and management of adverse reactions of transfusion through hemovigilance. The Blood Bank Laboratory performs testing and preparing blood products to ensure the safest possible transfusion for our patients. Testing includes ABO/Rh typing, antibody screening and/or identification, and cross matching blood units in preparation for transfusion, in addition to higher level testing including platelet refractoriness work-ups and phenotyping. We use the most advanced and automated methods of testing to provide rapid, accurate test results.

The Apheresis Service at the Mount Sinai Hospital supports our clinical teams in providing patients with effective therapies and life-saving treatments using several different therapeutic apheresis procedures including plasmapheresis, erythrocytapheresis, plateletpheresis, and extracorporeal photopheresis. Furthermore, the apheresis service plays a supportive role in cellular therapy through the collection of stem cells or mononuclear cells for transplantation or manufacturing of advanced cell therapies. As physicians working hand in hand with a team of highly skilled apheresis nurses, our Apheresis Service faculty and staff play a critical role in providing procedural oversight of the service.

The Cellular Therapy Laboratory at Mount Sinai Hospital provides services that enable more than 300 stem cell transplants and infusions of cell-based therapies performed annually. The laboratory is responsible for processing, storage and preparation for infusion of autologous and allogeneic cellular therapy products including stem cells, immune effector cells and other cell-based therapeutics.



*Transfusion Medicine and Cellular Therapy Faculty: from bottom left: **Suzanne Arinsburg, DO**, Associate Professor & System Director, Blood Bank and Transfusion Services and Director, Blood Bank and Transfusion Services Mount Sinai Hospital; **Kristin Sticco, DO**, Assistant Professor & Director Blood Bank Mount Sinai South Nassau; **Beth Raju, MD**, Assistant Professor & Assistant Director, Blood Bank and Transfusion Services Mount Sinai Hospital; from top left: **Philip Howard, MD**, Assistant Professor & Director, Blood Bank Mount Sinai West and Morningside; **Taylor Van Denakker, MD** Assistant Professor & Assistant Director, Blood Bank and Transfusion Services Mount Sinai Hospital; **Camelia Iancu-Rubin, PhD**, Professor & Director, Cellular Therapy Laboratory Mount Sinai Hospital; **Ian Baine, MD, PhD**, Assistant Professor & Assistant Director, Blood Bank and Transfusion Services and Director, Apheresis Services, Mount Sinai Hospital; not pictured, **Kathleen Leonard, MD**, Assistant Professor & Director, Blood Bank Mount Sinai Brooklyn and The Blavatnik Family Chelsea Cancer Center”.*

We perform thousands of procedures annually including but not limited to processing of bone marrow, peripheral and cord blood stem cells, handling FDA-approved and investigational cell-based therapies, performing quality control testing, cryopreservation, managing inventory and storage of thousands of cryopreserved cellular therapy products in safe and controlled conditions, and preparation of cell products for infusion. Our Laboratory contributes to delivering new and promising cell-based approaches to the bedside for treating diseases and conditions that were previously difficult to manage or incurable.

Current research focuses on improving blood storage methods, developing artificial blood substitutes, and enhancing transfusion safety. Similarly, innovative approaches are being evaluated to improve cell isolation and expansion techniques, storage and development of gene and cell therapies. In addition to attending standard of care, Transfusion Medicine faculty and staff are directly involved in clinical research efforts dedicated to bringing groundbreaking treatments to our patients.

Honored for Excellence: Dr. Carlos Cordon-Cardo Receives the Prestigious Latido Award

Dr. Carlos Cordon-Cardo received the “Latido Award for Excellence” from Medicina Responsable, a distinguished recognition granted annually in Spain to honor transformative contributions to medicine and society. This award reflects a lifetime dedicated to advancing personalized medicine, particularly in service of patients with cancer. It recognizes our collective efforts in pioneering research into mechanisms of drug resistance and the individualization of therapeutic strategies; the vision and clinical implementation of molecular pathology as a cornerstone of modern diagnostics; the integration of artificial intelligence and digital pathology into routine practice; our international contributions during the COVID-19 pandemic; and our ongoing commitment to building sustainable healthcare infrastructures in low-resource nations, such as the work underway in Guyana, which is now receiving increasing international attention. The award ceremony took place in Madrid, Spain on June 19, 2025.



Trailblazing Medicine: Lauren Singelakis Among the Top 50 Women Leaders in Medicine, 2024



Lauren Singelakis is currently the Vice President of Laboratory Operations, at the Department of Pathology, Molecular & Cell-Based Medicine for the Mount Sinai Health System in New York City. In her current role, she has operational and financial oversight for seven hospital-based laboratories as well as multiple system ambulatory labs. Here, she strives to develop and implement innovative initiatives; delivering system efficiency and exceptional quality.

Prior to joining the Mt Sinai Health System, Ms. Singelakis spent 9 years at Westchester Medical Center where she established and grew a revenue-generating outreach business for the lab. In addition, she and her team in-sourced Blood Bank and Transfusion Medicine; a service that was previously vendor-managed for 40+ years.

Ahead of this role, Lauren dedicated 13 years of her career to Public Health, serving as the Senior Virologist for the Westchester County Department of Laboratories and Research. There, she honed her skillset in laboratory medicine. One of her team's most notable accomplishments was isolating a strain of Influenza that was characterized by exceptional growth properties and utilized for the 2005-2006 Northern Hemisphere vaccine & 2006 Southern Hemisphere vaccine. In addition, she led teams that worked on the creation of West Nile Virus testing and collaborated with the CDC and WHO during the 2009 H1N1 Swine Flu Pandemic.

Lauren's interest and passion for laboratory medicine began in the late 1990's when she joined Montefiore Medical Center as a Laboratory Technologist; working on the early iteration of PCR for HIV Viral Load. Here she was not only intrigued by the science but the functionality of the laboratory as a whole.

She remains an advocate of supporting young women in STEM and served as a mentor in the “Her Honor” program founded by Judge Judy Sheindlin. Lauren is committed to educating the next generation of laboratory scientists and served on the planning and curriculum committee for the development of the Clinical Laboratory Science Master's Program at New York Medical College; where she was also an instructor. She currently serves as a board member for the New York State Clinical Laboratory Association and the Alumni Council for Mercy University. Ms. Singelakis' scientific knowledge coupled with her drive for operational excellence has forged her career pathways and led to her success.

Lauren earned a Bachelor's Degree in Biology from Manhattan College in 1996 and an MS in Health Care Management from Mercy University in 2018. She is currently pursuing certification as a Diplomate in Laboratory Management by the American Society for Clinical Pathology.



MSH Team from L to R: Weijie Li, Hayden Harris, Jeremy Littlefield, Shariah Pope, Liuba Correa, Shevaun Solomon and Audrey Ramirez (not in picture: MSH-ISOM grossing PAs - Caridad Fortune, Ma Theresa Alcantara, Raima Pavana, Sumreen Gul, Henry Chanderdatt, Shamim (Ahmed) Shamim, Celeste Prado Trinidad, Mohammed Zaman, Nhan Nguyen and Hilal Khan).

With more than 100,000 specimens being processed monthly, amounting to millions of slides/digital scans produced yearly, it is duly appropriate and deserving to take an in-depth look at the ‘heart and soul’ of this Pathology machine behemoth of Mount Sinai: the Grossing Hubs at Mount Sinai Morningside (MSM) and at Mount Sinai Hospital (MSH). Pathology dissection and microscopic analysis of specimens represent the historic starting point of all Pathology reporting. From complex surgical specimens to the many diverse minute biopsies, with specimens originating from all of our System Hospitals to include Mount Sinai West (MSW), Mount Sinai Brooklyn, Mount Sinai Queens, and Mount Sinai Nassau, suffice it to say we have the most top notch, world class grossing Pathologists Assistants (PA) teams. The Mount Sinai Department of Pathology grossing operation is completely centralized at these sophisticated cutting-edge Grossing Hubs at MSM and MSH. Each Grossing Hub is equipped with state-of-the-art brand new grossing stations, each offering the most updated computer hardware/connectivity, dissecting instruments, AV connections and sophisticated hydraulics. The stations are occupied by the two PA Grossing Teams. Both teams represent the pumping heart of our Pathology machine (along with our world class Residents of course), producing the very essential initial step of specimen processing that feeds our world renown 100% fully Digitized Pathology System

At **MSM**, the team is headed by **Chinelo Okpaleke (CJ)**. I had a moment to talk to CJ recently asking her what really motivated her to be a Pathology PA, her answer was very touching: “During my senior year of undergrad, I came across an article about a Pathologist who discovered a new brain lesion in football players, now known as CTE. That sparked my passion for understanding how diseases manifest and impact the human body. I became especially drawn to the role of a PA because it allows me to learn constantly while applying my skills in a hands-on setting. I take pride in the responsibility we have to accurately describe the pathology of lesions—often those that can’t be identified by scans alone—and to contribute meaningful insight into each patient’s case”;



MSM Team from L to R, first row: Heather Bool, Margeaux Villarosa, Mark Choi, Mariana Salibhanna. Back row, L to R: Pedrica Belizaire, Chinelo (CJ) Okpaleke, Andre Savaille



The MSM & MSH Grossing Hubs.. An In-Depth Look

by Dr. Ippolito Modica

CJ went on to praise the accomplishments the team at MSM headed by her have achieved in record time “In May 2024, I stepped into the role of Acting PA Operations Manager at MSM, after previously serving as the Travel PA for the grossing site. When the MSM grossing hub first launched, we had only three active PAs processing around 100 specimens daily from South Nassau, MSW, 10 Union, and MSM. Since then, our operations have grown significantly”, she says. Indeed, we appreciate the passion and hard work, of CJ and all her MSM PA Grossing team members **Heather Bool, Margeaux Villarosa, Mark Choi, Mariana Salibhanna, Andre Savaille, Pedrica Belizaire, Kenelia Mclean**.

At **MSH**, the team is headed by **Jeremy Littlefield (Jerr)**. I also had a moment to track down Jeremy and asked him what motivated him to be a Pathology PA: “I always had an interest in anatomy and searching for graduate-level anatomy programs I stumbled across Drexel’s pathologists’ assistant program. I shadowed a PA and then applied to Drexel.” Jeremy also then commented on the equally tremendous advancements the Grossing Hub at MSH has achieved and recently underwent while at the helm: “We have gotten several new state-of-the-art grossing stations and are on the cusp of starting whole mounting prostates.” The MSH PA Grossing team members include **Bing Miller, Weijie Li, Shariah Pope, Kahlil Goldson, Hayden Harris, Liuba Correa, Shevaun Solomon and Audrey Ramirez**. MSH-ISOM team includes; **Caridad Fortune, Ma Theresa Alcantara, Raima Pavana, Sumreen Gul, Henry Chanderdatt, Shamim (Ahmed) Shamim, Celeste Prado Trinidad, Mohammed Zaman, Nhan Nguyen and Hilal Khan**. Both MSH and MSH ISOM teams are undoubtedly a hardworking and passionate teams as well.

Please take a moment and say hello and express some appreciation when visiting these sites in your very busy schedules!

In Photos — A collection of events and moments that define us



Wellness Activities





USCAP



Fellowship Fair



Trainee Research Day 2025



LAB WEEK and other events



2024 - 2025 Compiled List of Pathology Faculty Publications

1. Avigan ZA, **Arinsburg SA**, Pan D, Mark T, Fausel C, Bubalo J Milkovich G, Moshier E, Fu W, Chari A, Richter J. *Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma*. Bone Marrow Transplant. 2024. 59(10):1440-1448.
2. Weiss S, Lin HM, Acosta E, Komarova NL, Chen P, Wodarz D, Baine I, Duerr R, Wajnberg A, Gervais A, Bastard P, Casanova JL, **Arinsburg SA**, Swartz TH, Aberg JA, Bouvier NM, Liu ST, Alvarez RA, Chen BK. *Post-transfusion activation of coagulation pathways during severe COVID-19 correlates with COVID-19 convalescent plasma antibody profiles*. J Clin Invest. 2025. 135(6):e181136.
3. Annen K, Andani S, Bosma G, Abbott D, **Arinsburg SA**, Nguyen F, Ibeh N, Nicol K, Hernandez P, Jackups R, Delaney M, Bahar B, Mo Y, Alexander B, Noland DK, Wong TE, Andrews J. *O blood usage trends in the pediatric population 20015-2019: A multi-institutional analysis*. Transfusion. 2025;65(4):676-683
4. Li P, Haines GK, Si Q, **Baskovich B**. *Post-therapeutic squamous cell transformation of a metastatic prostate adenocarcinoma with comparison of molecular profiles: a case report and review of the literature*. Int J Clin Exp Pathol 2024 Mar 15;17(3):78–82.
5. Bendari, A, Sham, S, Hammoud, H, Vele, O, **Baskovich, B**, Huang, D, Bendari, A, Saks, R, Al-Refai, R, Bendari, T et al. *Comprehensive Analysis of Factors Influencing Recurrence and Survival in Glioblastoma: Implications for Treatment Strategies: A Single Center Study*. J. Mol. Pathol. 2024, 5, 520-532.
6. Hectman J, **Baskovich B**, Fussell A, Geiersbach K, Iorgulescu JB, Sirohi D, Snow A, Sidiropoulos N. *Charting the Genomic Frontier: 25 Years of Evolution and Future Prospects in Molecular Diagnostics for Solid Tumors*. The Journal of Molecular Diagnostics, Volume 27, Issue 1, 2025, Pages 6–11, ISSN 1525-1578.
7. Liu, BL, Mehrotra, M, Kowtha, L, Guan, M, Houldsworth, J, **Baskovich, B**, **Harigopal, M**. *Fibroepithelial Neoplasm with Hybrid Features of Benign Phylloides Tumor, Juvenile Papillomatosis, and Juvenile Fibroadenoma: A Case Report*. International Journal of Surgical Pathology 2025; 33(1), pp.220-228.
8. Alkhasawneh A, **Baskovich B**, Gopinath A, Allan R., Mohamed A. and Quan W. *Interactive Pathology Tutorial in Neoplastic Hematology Disorders for Medical Hematology-Oncology Fellows*. Journal of Cancer Education 2024; 39(4), pp.413-417.
9. Chaddha U, Agrawal A, Ghoru U, Kheir F, ... **Beasley MB**, et al. *Safety and Sample Adequacy for Comprehensive Biomarker Testing of Bronchoscopic Biopsies: An American Association of Bronchology and Interventional Pulmonology (AABIP) and International Association for the Study of Lung Cancer (IASLC) Clinical Practice Guideline*. J Thorac Oncol. 2025 May 24;S1556-0864(25)00722-1. doi: 10.1016/j.jtho.2025.05.014. Epub ahead of print. PMID: 40419141.
10. Zhang J, Yip R, Taioli E, Flores RM, Henschke CI, Yankelevitz DF, Schwartz RM; IELCART Investigators (**Beasley MB** and **Zakowski M**). *Quality of life outcomes after robotic-assisted and video-assisted thoracoscopic surgery for early-stage non-small cell lung cancer*. JTCVS Open. 2025 Jan 21;24:383-393. doi: 10.1016/j.jxon.2025.01.007. PMID: 40309679; PMCID: PMC12039430.
11. Thunnissen E, Blaauwgeers H, Filipello F, Lissenberg-Witte B, Minami Y, Noguchi M, Quesne JL, Papotti MG, Flieder D, B. ... **Beasley MB**, Arrigoni G, et al. *A reproducibility study on invasion in small pulmonary adenocarcinoma according to the WHO and a modified classification, supported by biomarkers*. Lung Cancer. 2025 Jan;199:108060. doi: 10.1016/j.lungcan.2024.108060. Epub 2024 Dec 19.
12. **Beasley MB**. *Interstitial Lung Abnormalities*. Surg Pathol Clin. 2024 Jun;17(2):215-225. doi: 10.1016/j.path.2023.11.007. Epub 2023 Dec 20. PMID: 38692806.
13. **Beasley MB**. *Immunohistochemistry of Lung Cancer Biomarkers*. Adv Anat Pathol. 2024 Sep 1;31(5):333-343. doi: 10.1097/PAP.0000000000000450. Epub 2024 Apr 26. PMID: 38666761.
14. Shukla S, **Brandwein-Weber M**, Samankan S, Ayad A, Rabie M, Doyle S. *Federated learning in computational pathology: classification of tall cell patterns in papillary thyroid carcinoma*. Proc. SPIE 12933, Medical Imaging (2024): Digital and Computational Pathology, 129330U (3 April 2024); <https://doi.org/10.1117/12.3006890>
15. Yun JY, Kapustin D, Joseph J; Su V, Ramirez R, Rubin SJ, Khan MN, Chai R, Karasick M, Wiedmer C, **Brandwein-Weber M**, Urken ML: *Improving Interdisciplinary Communication and Pathology Reporting for Head and Neck Cancer Resections: 3D Visualizations and Margin Reconciliation*. Head and Neck Pathol J. (2024) doi: 10.1007/s12105-024-01684-9. PMID: 39153096; PMCID: PMC11330424.
16. Sayeed S, Kapustin D, Rubin SJ, Fan J, Wiedmer C, Chung D, Khorsandi A, **Brandwein-Weber M**, Friedlander P, Bakst R, Ramirez RJ, Urken ML. *Metastatic Merkel cell carcinoma to the thyroid gland: Case report and review of the literature*. Am J Otolaryngol. (2024) 10.1016/j.amjoto. 2024.104278. PMID: 38604100.
17. Yoon M, Ramirez R, Yun J, Wiedmer C, **Brandwein-Weber M**, Khorsandi AS, Buchbinder D, Khan MN. *Concurrent Oral Squamous Cell Carcinoma and Bisphosphonate-Related Osteonecrosis of the Maxilla: A Case Report and Literature Review*. Head Neck. (2024) doi: 10.1002/hed.27974. PMID: 39463136.
18. Berrios AB, Monaghan M, **Brandwein-Weber M**, van Gerwen M. *Investigating the Association between Hashimoto's Thyroiditis and Papillary Thyroid Cancer*. Head Neck. (2024) doi.org/10.1002/hed.28031.
19. Urken ML, **Brandwein-Weber M**, Chai RL, Zafereo M, et al. *When Thyroid Cancer Invades Adjacent Anatomy- Introducing an Anatomical Checklist to Bridge the Information Gap from Surgeon to Pathologist*. European Thyroid Journal 2025 <https://doi.org/10.1530/ETJ-24-0289>.
20. Legala A, Shukla S, Khare P, Veremis B, Aschheim K, **Brandwein M**, Schwendicke F, et al. *Quantification and mitigation of site-specific differences in digital pathology datasets*. Proc. SPIE 13413, Medical Imaging 2025: Digital and Computational Pathology, 134130W (10 April 2025); <https://doi.org/10.1117/12.3046519>
21. Sayeed S, Joseph J, Stanisce L, Ramirez R, Khorsandi A, **Brandwein-Weber M**, Urken ML: *Undescended Ectopic Parathyroid Adenoma Within Ectopic Cervical Thymus in the Carotid Sheath*. Head and Neck Case Reports. <https://doi.org/10.1002/hed.28176>
22. Comess SR, Joseph J, Yoon M, Sayeed S, Borkhetaria P, Stanisce L, **Brandwein-Weber, M**, Karasick M, Urken ML: *Identifying and Closing Information Gaps in head and neck cancer surgery*. Seminars Oncology. <https://doi.org/10.1016/j.seminoncol.2025.152362>.
23. Samankan, S, Shahid, R, Saleem, H, Katragaddam, SC, **Brandwein-Weber, M**, Prasad S: *Oncocytic Chondro Osseous Respiratory Epithelial Hamartoma: Expanding the Histological Variants of CORE Hamartoma and Literature Review*. Clinics of Surgery. (in press)
24. Karasick M, Joseph J, Yoon M, Comess SR, Sayeed S, Borkhetaria P, Stanisce L, **Brandwein-Weber M**, Urken ML: *MarginView3D: Novel Software to Enable 3-Dimension Visualization of Margin Mapping and Comprehensive Anatomic/Pathologic Reporting*. Annals of Surgical Oncology. (in press).
25. Troxel AB, Bind MC, Flotte TJ, **Cordon-Cardo C**, Decker LA, et al. Researching COVID to enhance recovery (RECOVER) tissue pathology study protocol: Rationale, objectives, and design. PLoS One 19(1):e0285645, 2024. doi: 10.1371/journal.pone.0285645. PMID: 3819848
26. Kapustin D, Su V, Yun, J, Rubin, SJ, **Chung D**, **Modica I**, Khan M.N, Chai RL, Karasick M, Doyle S, **Brandwein-Weber M**, Urken, ML. *iPad Annotation of 3D Surgical Models Using Procreate*: Novel Documentation of Supplemental Margins*. The Laryngoscope 2024;134: 2783-2786.
27. Carossino M, Izadmehr S, Trujillo JD, Gaudreault NN, Dittmar W, Morozov I, Balasuriya UBR, **Cordon-Cardo C**, Garcia-Sastre A, Richt JA. *ACE2 and TMPRSS2 distribution in the respiratory tract of different animal species and its correlation with SARS-CoV-2 tissue tropism*. Microbiol Spectr 12:e0327023, 2024. doi: 10.1128/spectrum.03270-23. PMID: 38230954
28. Busby D, Grauer R, Pandav K, Khosla A, Jain P, Menon M, Haines GK 3rd, **Cordon-Cardo C**, Gorin MA, Tewari AK. *Applications of artificial intelligence in*

- prostate cancer histopathology*. Urol Oncol 42(3):37-47. 2024. doi: 10.1016/j.urolonc.2022.12.002.
29. Izadmehr S, Fernandez-Hernandez H, Wiredja D, Kirschenbaum A, Lee-Poturski C, Tavassoli P, Yao S, Schlatter D, Hoon D, Difeo A, Levine AC, Mosquera JM, Galsky MD, **Cordon-Cardo C**, Narla G. *Cooperativity of c-MYC with Krüppel-Like Factor 6 Splice Variant 1 induces phenotypic plasticity and promotes prostate cancer progression and metastasis*. bioRxiv [Preprint]. 2024 Feb 1:2024.01.30.577982. doi: 10.1101/2024.01.30.577982. PMID: 38352401
30. Wang L, Izadmehr S, Sfakianos JP, Tran M, Beaumont KG, **Brody R**, **Cordon-Cardo C**, Horowitz A, Sebra R, Oh WK, Bhardwaj N, Galsky MD, Zhu J. *Single-cell transcriptomic-informed deconvolution of bulk data identifies immune checkpoint blockade resistance in urothelial cancer*. iScience 27(6):109928, 2024. doi: 10.1016/j.isci.2024.109928. PMID: 38812546
31. Dogra N, Chen TY, Gonzalez-Kozlova E, Miceli R, **Cordon-Cardo C**, Tewari AK, Losic B, Stolovitzky G. *Extracellular vesicles carry transcriptional 'dark matter' revealing tissue-specific information*. J Extracell Vesicles. 2024 Aug;13(8):e12481. doi: 10.1002/jev2.12481.
32. Mack PC, Crawford JM, Chang A, Yin A, Klein SL, Shea P, ... C, **McBride R**, **Cordon-Cardo C**, VanOudenhoove J, Halene S, et al. *In the time of COVID-19: challenges, successes and lessons learned from studies in cancer patients*. J Natl Cancer Inst. 2025 Mar 24:djaf073. doi: 10.1093/jnci/djaf073.
33. Rana MM, Haydel B, Carrara G, Gleason C, Mauldin J, Srivastava K, Florman SS, Aberg J, van Kesteren M, Mischka J, Carreño JM, Singh G, **Mendu DR**, TITAN Study Group; Wajnberg A, **Cordon-Cardo C**, Krammer F, Simon V. *Humoral SARS-CoV-2 vaccine responses are durable in solid organ transplant recipients with and without HIV*. medRxiv [Preprint]. 2025 May 8:2025.05.07.25327192. doi: 10.1101/2025.05.07.25327192.
34. Kirthika P, Jawalagatti V, Li P, Xu M, Carceles-Cordon M, Ertel A, Quinn SA, Petrylak DP, Orme JJ, Dehm SM, Antonarakis ES, Heath EI, Pandey MK, **Cordon-Cardo C**, Huang H, et al. *Off-pore nucleoporin sPOM121 transcriptionally propels β -Catenin driven tumor progression and immune escape in prostate cancer*. Cancer Discov 2025 Jul 28 doi:10.1158/2159-8290.CD-25.
35. Marsan E, Gutman D, Hohman TJ, Phatak M, Dugger BN, Andersh K, Brannelly P, **Crary JF**, Nalls MA; Center for Alzheimer's and Related Dementias at the National Institutes of Health, the 10000 Brains Project, and the Path-ND collaborators. Marsan E, Gutman D, Hohman TJ, et al. *The Path-NeuroDegeneration consortium*. Lancet Neurol 2025;24(6):482. DOI: 10.1016/S1474-4422(25)00161-9.
36. Emrani S, Koutures A, Tripodis Y, Uretsky M, Abdolmohammadi B, Nowinski C, Daneshvar DH, Dwyer B, Katz DI, Goldstein LE, Cantu RC, Martin BM, Palmisano JN, Dams-O'Connor K, **Crary JF**, Stern RA, Mez J, Alvarez VE, Huber BR, McKee AC, Stein TD, Allosco ML. *Characterizing white matter and vascular pathologies in brain donors exposed to repetitive head impacts*. Acta Neuropathol 2025;149(1):24. DOI: 10.1007/s00401-025-02860-z.
37. Almeida FC, Santos A, Jesus T, Coelho A, Quintas-Neves M, Gauthreaux K, Mock CN, Kukull WA, **Crary JF**, Oliveira TG. *Lewy body co-pathology in Alzheimer's disease and primary age-related tauopathy contributes to differential neuropathological, cognitive, and brain atrophy patterns*. Alzheimers Dement 2025;21(1):e14191. DOI: 10.1002/alz.14191.
38. Wise A, Ortega RA, Raymond D, Cervera A, Thorn E, Leaver K, Russell DS, Bressman SB, **Crary JF**, Saunders-Pullman R. *Multiple sclerosis in LRRK2 G2019S Parkinson's disease and isolated nigral degeneration in a homozygous variant carrier*. Front Neurol 2024;15:1450654. DOI: 10.3389/fneur.2024.1450654.
39. Uretsky M, Nair E, Burton R, Cronin SW, Rousseau D, Tuz-Zahra F, Durape S, Abdolmohammadi B, Baucom Z, Saltiel N, Shah A, Martin B, Palmisano J, Cherry JD, Daneshvar D, Dwyer B, Dams-O'Connor K, **Crary J**, et al. *Chronic Traumatic Encephalopathy, Family History of Mental Illness, and Aggression in Brain Donors With Repetitive Head Impact Exposure*. Neurology 2024;103(12):e210056. DOI: 10.1212/WNL.000000000000210056.
40. Quintas-Neves M, Almeida FC, Gauthreaux K, Teylan MA, Mock CN, Kukull WA, **Crary JF**, Oliveira TG. *Fazekas scale magnetic resonance imaging assessment in Alzheimer's disease and primary age-related tauopathy*. Neuroradiology 2024;66(12):2185-2193.
41. Kovacs GG, Grinberg LT, Halliday G, Alafuzoff I, Dugger BN, Murayama S, Forrest SL, Martinez-Valbuena I, Tanaka H, Kon T, Yoshida K, Jaunmuktane Z, Spina S, Nelson PT, Gentleman S, Alegre-Abarrategui J, Serrano GE, Paes VR, Takao M, Wakabayashi K, Uchihara T, Yoshida M, Saito Y, Kofler J, Rodriguez RD, Gelpi E, Attems J, **Crary JF**, et al. *Biomarker-Based Approach to alpha-Synucleinopathies: Lessons from Neuropathology*. Mov Disord 2024;39(12):2173-2179. DOI: 10.1002/mds.30028.
42. Huang Y, Wang M, Ni H, Zhang J, Li A, Hu B, Junqueira Alves C, Wahane S, Rios de Anda M, Ho L, Li Y, Kang S, Neff R, Kostic A, Buxbaum JD, **Crary JF**, et al. *Regulation of cell distancing in peri-plaque glial nets by Plexin-B1 affects glial activation and amyloid compaction in Alzheimer's disease*. Nat Neurosci 2024;27(8):1489-1504.
43. **Farrell K**, Humphrey J, Chang T, Zhao Y, Leung YY, Kuksa PP, Patil V, Lee WP, Kuzma AB, Valladares O, Cantwell LB, Wang H, Ravi A, ... Mok KY, Rademakers R, Dickson DW, Ross OA, Wang LS, Goate A, Schellenberg G, Geschwind DH; PSP Genetics Study Group; **Crary JF**, et al. Author Correction: *Genetic, transcriptomic, histological, and biochemical analysis of progressive supranuclear palsy implicates glial activation and novel risk genes*. Nat Commun 2024;15(1):9828. DOI: 10.1038/s41467-024-53617-3.
44. Culhane JE, Jackson CE, Tripodis Y, Nowinski CJ, Dams-O'Connor K, Pettway E, Uretsky M, Abdolmohammadi B, Nair E, Martin B, Palmisano J, Katz DI, Dwyer B, Daneshvar DH, Goldstein LE, Kowall NW, Cantu RC, Stern RA, Huber BR, **Crary JF**, et al. *Lack of Association of Informant-Reported Traumatic Brain Injury and Chronic Traumatic Encephalopathy*. J Neurotrauma 2024;41(11-12):1399-1408. DOI: 10.1089/neu.2023.0391.
45. **Crary JF**. *Neurodegeneration: 2024 update*. Free Neuropathol 2024;5:31. DOI: 10.17879/freeneuropathology-2024-5848.
46. Almeida FC, Jesus T, Coelho A, Quintas-Neves M, Gauthreaux K, Teylan MA, Mock CN, Kukull WA, **Crary JF**, Oliveira TG. *Psychosis in Alzheimer's disease is associated with specific changes in brain MRI volume, cognition and neuropathology*. Neurobiol Aging 2024;138:10-18. DOI: 10.1016/j.neurobiolaging.2024.02.013.
47. Adams JW, Kirsch D, Calderazzo SM, Tuz-Zahra F, Tripodis Y, Mez J, Allosco ML, Alvarez VE, Huber BR, Kubilus C, Cormier KA, Nicks R, Uretsky M, Nair E, Kuzyk E, Aytan N, Cherry JD, **Crary JF**, et al. *Substantia Nigra Pathology, Contact Sports Play, and Parkinsonism in Chronic Traumatic Encephalopathy*. JAMA Neurol 2024;81(9):916-924.
48. Abdolmohammadi B, Tuz-Zahra F, Uretsky M, Nicks R, Mosaheb S, Labonte J, Yhang E, Durape S, Martin B, Palmisano J, Nowinski C, Cherry JD, Alvarez VE, Huber BR, Dams-O'Connor K, **Crary J**, et al. *Duration of Ice Hockey Play and Chronic Traumatic Encephalopathy*. JAMA Netw Open 2024;7(12):e2449106.
49. Chawla AS, Vandereyken M, Arias M, Santiago L, Dikovskaya D, Nguyen C, Skariah N, Wenner N, Golovchenko NB, Thomson SJ, Ondari E, Garzón-Tituaña M, Anderson CJ, Bergkessel M, Hinton JCD, **Edelblum KL**, Pardo J, Swamy M. *Distinct cell death pathways induced by granzymes collectively protect against intestinal Salmonella infection*. Mucosal Immunol. 2024 Aug 11:S1933-019(24)0087-4.
50. Fischer MA, Jia L, **Edelblum KL**. *Type I interferon induces TCR-dependent and -independent antimicrobial responses in gd intraepithelial lymphocytes*. J Immunol. 2024 Nov 1;213(9):1380-1391.
51. Xu W*, Golovchenko NB*, Martínez-Vargas, IU, Fong A, Rout P, Achi S, Bucar EB, Hsieh JJ, Vidmar KJ, Zhang L, **Polydorides AD**, Prinz I, Kollias G, Frey MR, Pizarro TT, Verzi MP, **Edelblum KL**; *Dysregulation of gd intraepithelial lymphocytes precedes Crohn's disease-like ileitis*. Sci Immunol. 2025 Mar 21;10(105):eadk7429. *co-first authors
52. Desai N, Kudose S, Remotti HE, Del Portillo A, Fazlollahi L, Lee MJ, Xiong Y, Moreira RK, Salomao M, **Fiel MI**, Gonzalez RS, Misdraji J, Gill RM, Hart J, Kleiner DE, Drebber U, Bellizzi AM, Lagana SM. *Erythrophagocytosis is not a reproducible finding in liver biopsies, and is not associated with clinical diagnosis of hemophagocytic lymphohistiocytosis*. Virchows Arch 2024 Jan;484(1):61-69. Epub 2023 Nov 4. PMID: 37924345.
53. Patel K, Asrani SK, **Fiel MI**, Levine D, Leung DH, Duarte-Rojo A, Dranoff JA, Nayfeh T, Hasan B, Taddei TH, Alsawaf Y, et al. *Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline*. Hepatology. 2025 Jan 1;81(1):358-379. doi: 10.1097/HEP.0000000000000842.

54. Sterling RK, Duarte-Rojo A, Patel K, Asrani SK, Alsawas M, Dranoff JA, Fiel MI, Murad MH, Leung DH, et al. *AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis*. Hepatology. 2025 Feb 1;81(2):672-724. doi: 10.1097/HEP.0000000000000843. Epub 2024 Mar 15. PMID: 38489518.
55. Sterling RK, Patel K, Duarte-Rojo A, Asrani SK, Alsawas M, Dranoff JA, Fiel MI, et al. *AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis*. Hepatology. 2025 Jan 1;81(1):321-357. doi: 10.1097/HEP.0000000000000845. Epub 2024 Mar 15. PMID: 38489523.
56. Sterling RK, Asrani SK, Levine D, Duarte-Rojo A, Patel K, Fiel MI, Leung DH, et al. *AASLD Practice Guideline on noninvasive liver disease assessment of portal hypertension*. Hepatology. 2025 Mar 1;81(3):1060-1085. doi: 10.1097/HEP.0000000000000844. Epub 2024 Mar 15. PMID: 38489663.
57. Jain D, Khandakar B, Ni P, Kenney B, Qin L, Deshpande V, Fiel MI. *von Meyenburg complexes are more frequently associated with cholangiocarcinoma*. J Clin Pathol. 2025 Apr 17;78(5):300-306. doi: 10.1136/jcp-2024-209572. PMID: 38729770.
58. Macdonald JK, Taylor HB, Wang M, Delacourt A, Edge C, Lewin DN, Kubota N, Fujiwara N, Rasha F, Marquez CA, Ono A, Oka S, Chayama K, Lewis S, Taouli B, Schwartz M, Fiel MI, et al. *The Spatial Extracellular Proteomic Tumor Microenvironment Distinguishes Molecular Subtypes of Hepatocellular Carcinoma*. J Proteome Res. 2024 Sep 6;23(9):3791-3805. doi: 10.1021/acs.jproteome.4c00099. PMID: 38980715
59. Saravanan N, Demetris A, Fiel MI, Harrington C, Khurram NA, Schiano TD, Levitsky J. *Serum and tissue biomarkers of plasma cell-rich rejection in liver transplant recipients*. Am J Transplant. 2025 Feb;25(2):259-268. doi: 10.1016/j.ajt.2024.10.006. Epub 2024 Oct 9. PMID: 39393458.
60. D'Alessio A, Stefanini B, Blanter J, Adegbite B, Crowley F, Yip V, Slater S, Fulgenzi CAM, Celsa C, Manfredi GF, Pai M, Goldin RD, Ward SC, Fiel MI, et al. *Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis*. Lancet Oncol 2024 Nov;25(11):1465-1475. Epub 2024 Oct 19. PMID: 39437804;
61. Lindblad KE, Donne R, Liebling I, Bresnahan E, Barcena-Varela M, Lozano A, Park E, Giotti B, Burn O, Fiel MI, et al. *NOTCH1 drives tumor plasticity and metastasis in hepatocellular carcinoma*. bioRxiv [Preprint]. 2025 Mar 3:2024.10.23.619856. doi: 10.1101/2024.10.23.619856. PMID: 39484457; PMCID: PMC11527037.
62. Todd R, van Leeuwen LL, Holzner M, Kim-Schlager L, Fiel MI, Puleston D, Florman SS, Akhtar MZ. *Normothermic machine perfusion of explanted livers: Exploratory study of an alternative translational model for end-stage liver disease*. Artif Organs. 2025 Mar;49(3):431-440. Epub 2024 Nov 23. PMID: 39578939.
63. Dasani DB, Fiel MI, Simoes CC, Morgenthau AS, Schiano TD. *The Varying Histology of Hepatic Sarcoidosis and the Relation of Bile Duct Damage and Loss to the Presence of Portal Hypertension and Cirrhosis*. Gastro Hep Adv. 2024 Oct 10;4(2):100561. doi: 10.1016/j.gastha.2024.10.001. PMID: 39866718
64. Kaufman O, Donnelly C, Cork E, Fiel MI, Chu J, Ganesh J. *Shwachman-Diamond syndrome mimicking mitochondrial hepatopathy*. JPGN Rep. 2024 Mar 13;5(2):213-217. doi: 10.1002/jpr3.12064. PMID: 38756125; PMCID: PMC11093899.
65. Li P, Schiano TD, Thung SN, Ward SC, Fiel MI. *Shared Features of Obliterative Portal Venopathy, Normal Liver, and Chronic Liver Disease: A Histologic and Morphometric Analysis*. Mod Pathol. 2025 Jun;38(6):100739. doi: 10.1016/j.modpat.2025.100739. Epub 2025 Feb 20. PMID: 39986468.
66. Zhang L, Ali RO, Chamroonkul N, Tabrizian P, Schwartz M, Gunasekaran G, Schiano T, Fiel MI, Ward S, Bansal MB. *HIV-1 Amplifies IL-8 Response Of Human Stellate Cells To Gram-Positive Microbial Products Via H4K5 Histone Acetylation*. bioRxiv [Preprint]. 2025 May 15:2025.05.12.653460. PMID: 40462917.
67. Petitjean L, Chen L, Zhang X, Schiano T, Petitjean M, Sanyal AJ, Fiel M. *Digital Pathology Quantification of the Continuum of Cirrhosis Severity in Human Liver Biopsies*. Liver Int. 2025 Jul;45(7):e70166. doi: 10.1111/liv.70166. PMID: 40522259; PMCID: PMC12169097.
68. Zhang W, Houldsworth J, Schiano TD, Fiel MI. *Confirmation of the donor origin of de novo hepatocellular carcinoma after liver transplant using microsatellite analysis*. Am J Clin Pathol. 2025 Jul 23;aqaf078. doi: 10.1093/ajcp/aqaf078. Epub ahead of print. PMID: 40698910.
69. Heller A, Kowtha L, Tiwari K, Harigopal M. *Breast Pathology Through the Digital Lens*. Semin Diagn Pathol. 2025 Jul;42(4):150914. doi: 10.1016/j.semdp.2025.150914. Epub 2025 Apr 24. PMID: 40311533
70. Pareja F, Bhargava R, Borges VF, Brogi E, Canas Marques R, Cardoso F, Desmedt C, Harigopal M, et al. *Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes*. NPJ Breast Cancer. 2025 Jan 24;11(1):6. PMID: 39856067
71. Sun T, Golestani R, Zhan H, Krishnamurti U, Harigopal M, Zhong M, Liang Y. *Clinicopathological characteristics of MYC copy number amplification in Breast Cancer*. Int J Surg Pathol. 2024. PMID: 38839260
72. Ni P, Harpaz N, Altahrawi A, & Liu, Q. *Diagnostic and prognostic significance of Crohn's disease-like pathology in surgically diverted recta of patients with ulcerative colitis*. Histopathology 87, 81–89 (2025).
73. Magro F, Protic M, De Hertogh G, Chan LS, Pollack P, Jairath V, Carlier H, Hon E, Feagan BG, Harpaz N, Pai R, Reinisch W. *Effects of mirikizumab on histologic resolution of Crohn's disease in a randomized controlled phase 2 trial*. Clin Gastroenterol Hepatol 2024;22:1878–1888.
74. Magro F... Harpaz N, et al. *Early Histologic Response and Remission are Associated With Objective Control of Inflammation After One Year of Treatment With Mirikizumab in Moderately-to-Severely Active Crohn's Disease*. J Crohns Colitis 2025; 19:i188–i189.
75. Liu Q, Wang Y, Harpaz N. *Coexisting Th1 and Th2 cytokines in patients with collagenous gastritis and implications for its pathogenesis*. J Pediatr. Gastroenterol 2024; Nutr 78:231–240.
76. Levantovsky RM, Tastad C, Zhang J, Gettler K, Sabic K, Werner R, Chasteau K, Korie U, Paguay D, Bao M, Han H, Maskey N, Talware S, Patel M, Argmann C, Suarez-Farinas M, Harpaz N, et al. *Multimodal single-cell analyses reveal mechanisms of perianal fistula in diverse patients with Crohn's disease*. JH Med 2024;9;5(8):886-908.e11. PMID: 38663404.
77. Jairath V... Harpaz N et al. *S1330 Effects of Mirikizumab and Ustekinumab on Histologic Inflammation Evaluated by Comprehensive Assessment in 5 Intestinal Segments in a Randomized Controlled Phase 3 Trial of Participants With Crohn's Disease*. Off. J. Am. Coll. Gastroenterol. ACG 119, S953 (2024).
78. Jairath V... Harpaz N et al. *S1329 Effects of Mirikizumab versus Placebo on Histologic Inflammation Evaluated by Comprehensive Assessment in 5 Intestinal Segments in a Randomized, Controlled Phase 3 Trial of Participants With Crohn's Disease*. Off. J. Am. Coll. Gastroenterol. ACG 119, S952–S953 (2024).
79. Jones A, McBride RB, Laroux S, Jayson C, Harpaz N. *Mucosal Healing in Ulcerative Colitis: Definition, Treatment Target and Clinical Endpoints*. Union for European Gastroenterology, Berlin, Germany June 2025. Moderated abstract.
80. Wang X., Baek W., Liu Q., Harpaz N. *Pathological Characteristics of Colorectal Cancer and Dysplasia in Patients with Inflammatory Bowel Disease with and without Primary Sclerosing Cholangitis*. Lab Invest 2025;105(3):102944. Doi: 10.1016/j.labinv.2024.102944.
81. Tanager K, Li J, Ma C, Rubin D., Li P., Fiel MI., et al. *Clarifying the Histopathologic and Clinical Phenotype of Inflammatory Bowel Disease in Primary Sclerosing Cholangitis: A Multicenter Study*. Lab Invest 2025;105(3):102925. Doi: 10.1016/j.labinv.2024.102925.
82. Qiu W, Liu Q, Paulsen J, Wang X, Stock A, Jain S, et al. *Interobserver Agreement and Predictive Value of Grading Crypt Cell Atypia in Barrett Esophagus*. Lab Invest 2025;105(3):102905. Doi: 10.1016/j.labinv.2024.102905.
83. Mamilla D, Jain S, Harpaz N. *De Novo, Colonized, And Embedded: Distinct Patterns of Dysplasia In IBD-Associated Inflammatory Polyps*. Lab Invest 2025;105(3):102869. Doi: 10.1016/j.labinv.2024.102869.
84. Agrawal M., Hansen AV., Harpaz N., Colombel JF., Jess T., Allin KH. *Differential impact of appendectomy with appendiceal inflammation versus no inflammation on inflammatory bowel disease risk in a population-based cohort*. J Crohns Colitis 2025;19:i2252–3. Doi: 10.1093/ecco-jcc/jjae190.1418.

85. Yu C, Shen Q, Holmes AB, Mo T, Tosato A, Soni RK, Corinaldesi C, Koul S, Pasqualucci L, **Hussein S**, et al. *MEF2B C-terminal mutations enhance transcriptional activity and stability to drive B cell lymphomagenesis*. *Nat Commun* 2024;21:15(1):7195.
86. Corinaldesi C, Holmes AB, Martire G, Tosato A, Rizzato D, Lovisa F, Galligani I, Shen Q, Ferrone L, Harris M, Davies K, Molinaro L, Mortara U, Dei Tos AP, Ofori K, D'Amore ESG, Chiarle R, Ngan B, Carraro E, Pillon M, **Hussein S**, et al. *Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistance*. *Leukemia*. 2025 Jan;39(1):189-198. Sircy LM, Ramstead AG, Gibbs LC, **Joshi H**, Baessler A, Mena I, García-Sastre A, Emerson LL, Fairfax KC, Williams MA, Hale JS. *Generation of antigen-specific memory CD4 T cells by heterologous immunization enhances the magnitude of the germinal center response upon influenza infection*. *PLoS Pathog* 2024;16:20(9):e1011639. PMID: 39283916;
87. Thibaud S, Subaran RL, Newman S, Lagana A, Melnekoff DT, Bodnar S, Ram M, Soens Z, Genthe W, Brander T, Mouhieddine TH, Van Oekelen O, **Houldsworth J**, et al. *Multiple myeloma risk and outcomes are associated with pathogenic germline variants in DNA repair genes*. *Blood Cancer Discov*. 2024; 5:428-441.
88. Mutetwa T, **Liu Y**, Silvera R, Evans M, Yurich M, Tripodi J, Leonard I, **Houldsworth J**, Gümüş Z, Bowcock AM, Sigel K, Gaisa M, Polak P. *Host nuclear genome copy number variations identify high-risk anal precancers in people living with HIV*. *J Acquir Immune Defic Syndr*. 2024, 96:190-195.
89. Pratt VM, Akhavanfard S, **Houldsworth J**, Laffin JJ, Moyer AM, Reddi HV, Scott SA, Lebo MS; *Association for Molecular Pathology Genetics Subdivision Leadership*. *Twenty-five years of germline genetic testing and what may lie ahead*. *J Mol Diagn* 2024; 26:1038-41.
90. Campanella G, Chen S, Singh M, Verma R, Muehlstedt S, Zeng J, **Stock A**, Croken M, **Veremis B**, Elmas A, Shjuski I, Neittaanmaki N, Huang KL, **Kwan R**, **Houldsworth J**, Schoenfeld A, Vanderbilt C. *A clinical benchmark of public self-supervised pathology foundation models*. *Nature Commun*. 2025; Apr 17;16(1):3640 (in press).
91. Campanella G, Kumar N, Nanda S, Singi S, Fluder E, Kwan R, Muehlstedt S, Pfarr N, Schuffler PJ, Haggstrom I, Neittaanmaki N, Akyurek LM, Basnet A, Jamaspishvili T, Nasr MR, Croken MM, Hirsch FR, Elkrief A, Yu H, Ardon O, Goldgof GM, Hameed M, **Houldsworth J**, et al. C. *Real-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detection*. *Nature Med*. 2025; accepted.
92. Aleman A, Van Oekelen O, Melnekoff DT, Kappes K, Serebryakova K, Jackson H, Lu J, Chatikhine A, Kulkarni R, **Moinfar Z**, Croken MM, **Mehrotra M**, **Baskovich B**, Rayamajhi S, Richard S, Rossi AC, Salib C, **Houldsworth J**, et al. *Personalized targeted therapy of CAR+ T-cell lymphoma after anti-BCMA CAR-T*. *New Eng J Med*. 2025; accepted.
93. Garrood M, Keberle A, Sowa A, Janssen W, Thorn EL, De Sanctis C, **Farrell K**, **Crary JF**, McKenzie AT. *Evaluating ultrastructural preservation quality in banked brain tissue*. *Free Neuropathology* 6:13 (2025) PMID: 40567433
94. Han X., Zhang Y., Petrosky J.N., Bald S., Sherva R.M., Labadorf A., Cherry J.D., Chung J., **Farrell K.**, Abdolmohammadi B., Durape S., Martin B.M., Palmisano J.N., Farrell J.J., Alvarez V.E., Huber B.R., Dwyer B., Daneshvar D.H., Dams-O'Connor K., Jun G.R., Lunetta K.L., Goldstein L.E., Katz D.I., Cantu R.C., Shenton M.E., Cummings J.L., Reiman E.M., Stern R.A., Alosco M.L., Tripodis Y., Farrer L.A., Stein T.D, **Crary J.F.**, McKee A.C., Mez J. *A structural haplotype in the 17q21. 31 MAPT region is associated with increased risk for chronic traumatic encephalopathy endophenotypes*. *Cell Reports Medicine* 6:5 (2025)
95. Wang H, Chang TS, Dombroski BA, Cheng PL, Si YQ, Tucci A, Patil V, Valiente-Banuet L, Li C, **Farrell, K.**, McLean, C., Molina-Porcel, L., Rajput, A., De Deyn PP, Le Bastard N, Gearing M... Ludolph A., Burn D, et al. *Copy number variation and haplotype analysis of 17q21. 31 reveals increased risk associated with Progressive Supranuclear Palsy and gene expression changes in neuronal cells*. *Movement disorders* 40:5 (2025)
96. Garrood M, Thorn EL, Goldstein A, Sowa AS, Janssen W, Wilson A, López CS, Shankar R, Stempinski ES, **Farrell K**, **Crary JF**, McKenzie AT. *Preservation of cellular structure via immersion fixation in brain banking*. *Free Neuropathology* 6:4 (2025)
97. **Richardson TE**, Orr ME, Orr TC, Rohde SK, Ehrenberg J, Thorn L, Christie TD, Flores-Almazan V, Afzal R, De Sanctis C, **Maldonado-Díaz C**, Hiya S, Canbeldek L, Mahadevan LSK, **Slocum C**, **Samanamud J**, **Clare K**, **Scibetta N**, **Yokoda RT**, Koenigsberg D, Marx GA, Kauffman J, Goldstein A, Selmanovic E, Drummond E, Wisniewski T, White CL III, Goate AM, **Crary JF**, **Farrell K**, Alosco ML, Mez J, McKee AC, Stein TD, Bieniek KF, Kautz TF, Daoud EV, **Walker JM**. *Spatial proteomic differences in chronic traumatic encephalopathy, Alzheimer's disease, and primary age-related tauopathy hippocampi*. *Alzheimer's and Dementia* 21:2 (2025)
98. McKenzie AT, Thorn EL, Nnadi O, Wróbel B, Kendziorra E, **Farrell K**, **Crary JF** *Cryopreservation of brain cell structure: a review*. *Free Neuropathology* 5:35 (2025)
99. Whitney K, Song W-M, Sharma A, Dangoor DK, **Farrell K**, Krassner MM, Ressler HW, Christie TD, Kandoi S, Walker RH, Nirenberg MJ, Frucht SJ, Riboldi GM, Zhang B, Pereira AC, **Crary JF**. *Single-cell transcriptomic and neuropathologic analysis reveals dysregulation of the integrated stress response in progressive supranuclear palsy*. *Acta Neuropathologica* 148:1 (2025)
100. **Farrell K**, Humphrey J, Chang T, Zhao Y, Leung Y, Kuksa PP, Patil V, Lee W, Kuzma AB, Valladares O, Cantwell LB, Wang H, Ravi A, De Sanctis C. Wang L, Goate A, Schellenberg G, Geschwind DH, PSP genetics study group, **Crary J.F.***, Naj A.* *Genetic, transcriptomic, histological, and biochemical analysis of progressive supranuclear palsy implicates glial activation and novel risk genes* *Nature communications* 15 (1), 7880 (2024)
101. Ressler HW, Humphrey J, Vialle RA, Babrowicz B, Kandoi S, Raj T, Dickson DW, Ertekin-Taner N, **Crary JF**, **Farrell K**. *MAPT haplotype-associated transcriptomic changes in progressive supranuclear palsy* *Acta Neuropathologica Communications* 12:1 (2024)
102. Wang H, Chang TS, Dombroski BA, Cheng P-L, Patil V, Valiente-Banuet L, **Farrell K**, McLean C.... **Crary JF** et al. *PSP Genetics Study Group. Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy* *Molecular Neurodegeneration* 19:1 (2024)
103. **Maldonado-Díaz C**, Hiya S, Yokoda RT, **Farrell K**, Marx GA, Kauffman J, Daoud EV, Gonzales MM, Parker AS, Canbeldek L., Mahadevan LSK, **Crary JF**, White III C.L., **Walker JM**, **Richardson TE**. *Disentangling and quantifying the relative cognitive impact of concurrent mixed neurodegenerative pathologies*. *Acta Neuropathol* 147, 58 (2024)
104. **Walker JM**, Orr ME, Orr TC, Thorn EL, Christie TD, **Yokoda RT**, Vij M, Ehrenberg AJ, Marx GA, McKenzie AT, Kauffman J, Selmanovic E, Wisniewski T, Drummond E, White III CL, **Crary JF**, **Farrell K**, Kautz TF, Daoud EV, **Richardson T.E**. *Spatial proteomics of hippocampal subfield-specific pathology in Alzheimer's disease and primary age-related tauopathy*. *Alzheimer's Dement*. 20: 783–797 (2024)
105. Wang Q, Wang M, Choi I, Sarrafha L, Liang M, Ho L, **Farrell K**, Beaumont KG, Sebra R, De Sanctis C, **Crary JF**, Ahfeldt T, Blanchard J, Neavin D, Powell J, Davis DA, Sun X, Zhang B, Yue A. *Molecular profiling of human substantia nigra identifies diverse neuron types associated with vulnerability in Parkinson's disease*. *Science Advances* 10:2 (2024)
106. McKenzie AT, Nnadi O, Slagell KD, Thorn EL, **Farrell K**, **Crary JF**. *Fluid preservation in brain banking: a review*. *Free Neuropathol*. Apr 23;5:5-10. (2024)
107. Canbeldek L, **Yokoda RT**, Mahadevan LS, Suemitsu Y, **Samanamud J**, **Slocum C**, **Maldonado-Díaz C**, Hiya S, **Clare K**, Yong RL, **Umphlett M**, **Tsankova NM**, **Crary J**, Walker J, Naidich T, **Richardson TE**, *Antemortem radiologic and histopathologic presentation of Marchiafava-Bignami disease*. *Journal of Neuropathology & Experimental Neurology*. 2025.
108. Sheskier R, Verma P, Kirschenbaum A, Orelowitz B, **Umphlett M**, Sharif U, Sfakianos, J, Schlachter L, Bederson J, Levine A. *A rare case of metachronous pituitary germinoma and testicular seminoma: The role of tumor markers in diagnosis and the influence of glucocorticoids on disease progression*. *Journal of Clinical and Translational Endocrinology*. 2025;36. 100182.
109. Downes MH, Kalagara R, Rossitto CP, Vasan V; Devarshi Vasa; Susmita Chennareddy; Lefton DR; Yildiz S; **Umphlett M**; Brockington C. *Validation of the Boston Criteria Version 2.0 for Cerebral Amyloid Angiopathy in Patients Presenting With Intracerebral Hemorrhage*. *Neurology*. 2025;104(7):e213460. doi:10.1212/WNL.0000000000213460

110. Dullea JT, Chaluts D, Vasan V, Rutland JW, Gill CM, Ellis E, Kinoshita Y, McBride RB, Bederson J, Donovan M, Sebra R, Umphlett M, Shrivastava RK. *NF2 mutation associated with accelerated time to recurrence for older patients with atypical meningiomas*. Br J Neurosurg. 2025 Apr;39(2):173-179. doi: 10.1080/02688697.2023.2204927.
111. Dharmapuri S, Cabal R, Akturk G, Ioannou G, Ozbey S, Paulsen JD, Raina S, Ang C, Sarpel U, Sung MW, Kozuch P, Schwartz ME, Cohen DJ, Gnjatich S, Pintova S. *Multiplexed immunohistochemical analysis of the immune microenvironment of biliary tract cancers pre- & post-neoadjuvant chemotherapy: case series*. Ann Transl Med. 2024 Aug 1;12(4):78.
112. Wong SY, Estevinho MM, Heaney T, Marshall AA, Giselsbrecht E, Daniel SG, Zhou C, Rosas-Villegas A, Jang KK, Yang H, Ko HM, Paulsen JD, Ding Y, Bittering K, Cho JH, Lewis JD, Ramanan D, Cadwell K. *Goblet cell loss linked to NOD2 and secondary resection in Crohn's disease is induced by dysbiosis and epithelial MyD88*. Cell Mol Gastroenterol Hepatol. 2025 May 14:101533.
113. Kombak F, Liu Q, Paulsen J, Wang, X, Amlashi F, Pei H, Zheng W, Sigel K, Gaisa M, Polydorides A, Liu, Y (2025). *Challenges in Histological Diagnosis of Superficially Invasive Anal Squamous Cell Carcinoma*. Arch Pathol Lab Med (2025).
114. Musial LA and Ramer N. *Oral Myeloid Sarcoma*. NYSDJ (in press).
115. Richardson TE, Walker JM, Hambardzumyan D, Brem S, Hatanpaa KJ, Viapiano MS, Pai B, Umphlett M, Becher OJ, Snuderl M, McBrayer SK, Abdullah KG, Tsankova NM. *Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma*. Acta Neuropathologica 148(1): 5, 2024.
116. Hicks WH, Gattie LC, El Shami M, Traylor JI, Davar D, Najjar YG, Richardson TE, McBrayer SK, Abdullah KG. *Matched three-dimensional organoids and two-dimensional cell lines of melanoma brain metastases mirror response to targeted molecular therapy*. Scientific Reports 14(1): 24843, 2024.
117. Hiya S, Maldonado-Díaz C, Rohde SK, Gonzales MM, Canbeldek L, Kulamani Mahadevan LS, Yokoda RT, Sullivan AC, Parker AS, White CL, Daoud EV, Flores-Almazan V, Crary JF, Farrell K, Walker JM, Richardson TE. *Unraveling the clinical-pathological correlations of subjects with isolated and mixed neurodegenerative pathologies in the NACC dataset*. Journal of Neuropathology & Experimental Neurology 84(3): 177-194, 2025.
118. Anoop BN, Li K, Honnorat N, Rashid T, Wang D, Li J, Fadaee E, Charisis S, Walker JM, Richardson TE, Wolk DA, Fox PT, Cavazos JE, Seshadri S, Wisse LEM, Habes M. *Convolutional neural networks for the segmentation of hippocampal structures in postmortem MRI scans*. Journal of Neuroscience Methods 415: 110359, 2025.
119. Nguyen P, Yokoda RT, Hossain Q, Bederson JB, Richardson TE. *Solitary fibrous tumor-meningioma collision tumor with 18 years of follow-up*. Journal of Neuropathology & Experimental Neurology [Epub ahead of print]
120. Rohde SK, Luimes M, Lorenz LMC, Fierro-Hernández P, Rozemuller AJM, Netherlands Brain Bank, Hulsman M, Zhang M, Graat M, van der Hoorn M, Daatselaar D, Scheltens P, Richardson TE, Walker JM, Sikkes SAM, Hoozemans JJM, Holstege H. *Association of amyloid-beta pathology with cognitive performance in centenarians*. JAMA Neurology [Epub ahead of print]
121. Canan F, Wick N, Raisanen JM, Burns DK, Hatanpaa KJ, Richardson TE, White CL, Daoud EV. *Characterization of neurodegenerative pathologies in adult and pediatric subjects with Down syndrome*. Journal of Alzheimer's Disease [Accepted/in press]
122. Almeida FC, Marx GA, Rohde SK, Gonzales MM, Maldonado-Díaz C, Hiya S, Clare K, Samanamud J, Slocum CC, Kauffman J, Koenigsberg DG, Crary JF, Farrell K, White CL, Daoud EV, Walker JM, Oliveira TG, Richardson TE. *Cognitive and neuropsychological trajectories in patients with mixed neurodegenerative pathologies*. Alzheimer's & Dementia [Accepted/in press]
123. Groff KJ, Patel RV, Feng Y, Ghosh HS, Chavez MM, Chen WC, Nitturi V, Save A, Youngblood MW, Ehret F, Gui C, Wang JZ, Park K, Rosenblum M, Suwala AK, Kresbach C, Mount CW, Schüller U, Santagata S, Sahm F, Bale TJ, Jackson C, Richardson TE, Cai C, Nassiri F, Zadeh G, Kaul D, Capper D, Magill ST, Golfinos JG, Sen C, Patel AK, Raleigh DR, Günel JM, Pacione D, Snuderl M, Bi WL. *The impact of TERTp mutation on meningioma outcome is context-dependent: implications for clinical grading and risk stratification*. Lancet Oncology [Accepted/in press]
124. Klute S, Nchioua R, Cordsmeier A, Vishwakarma J, Koepke L,... **Sordillo EM**, van Bakel H, Simon V, Kirchhoff F, Jacob T, Kmiec D, Pichlmair A, Ensser A, Sparrer KMJ. *Mutation T9I in Envelope confers autophagy resistance to SARS-CoV-2 Omicron*. iScience 2025; 28 (7):112974 doi: 10.1016/j.isci.2025.112974
125. Hernandez C, Patiño LH, Camargo M, Wang CY, Chen F, Liggay B, Cao L, **Cordon-Cardo C, Sordillo EM, Paniz-Mondolfi A, Ramirez JD**. *Validation of Human Papillomavirus Genotyping by Oxford Nanopore Sequencing in Formalin-Fixed, Paraffin-Embedded Tissues and ThinPrep Anal and Gynecologic Samples*. J Mol Diagn. 2025;Jun 5:S1525-1578(25)00133-3. doi: 10.1016/j.jmoldx.2025.04.010. PMID: 40482884.
126. Fantin RF, Clark JJ, Cohn H, Jaiswal D, Bozarth B, Rao V, Civljak A, Lobo I, Nardulli JR, Srivastava K, Yong JS, Andreatta-Santos R, Bushfield K, Lee ES...**Sordillo EM**, Ramsamooj R, Kleinstein SH, Krammer F, Simon V, Bajic G, Coelho CH. *Mapping of human monoclonal antibody responses to XBB.1.5 COVID-19 monovalent vaccines: a B cell analysis*. Lancet Microbe 2025 May 30;101103. doi: 10.1016/j.lanmic.2025.101103. PMID: 40456237.
127. Nunes MC, Chauvel C, Raboni SM, López-Labrador FX, Andrew MK, Badar N, Baillie V, Bal A, Baral K, Baumeister E, Boutros C, Burtseva E, Coulibaly D, Cowling B, Danilenko D, Dbaibo G, Destras G, Dia N, Drăgănescu AC, Giamberardino HIG.... **Sordillo E**, Tanriover MD, Unal S, van Bakel H, Vanhems P, Zhang T, Commaillie-Chapus C, Hunsinger C, Bresee J, Lina B, McCauley JW, Ortiz JR, Viboud C, Zhang W, Torcel-Pagnon L, Mahe C, Chaves SS. *The Global Influenza Hospital Surveillance Network: A Multicountry Public Health Collaboration*. Influenza Other Respir Viruses. 2025 Mar;19(3):e70091. PMID: 40082217.
128. Rosales R, McGovern BL, Rodriguez ML, Leiva-Rebollo R, Diaz-Tapia R, Benjamin J, Rai DK, Cardin RD, Anderson AS, Alshammary H, Banu R, Farrugia K, Gonzalez-Reiche AS, Paniz-Mondolfi A, Polanco J, **Sordillo EM**, van Bakel H, Simon V, García-Sastre A, White KM. *Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants*. Antiviral Res. 2024 Oct; 230:105970. doi: 10.1016/j.antiviral.2024.105970. Epub 2024 Jul 25. PMID: 39067667.
129. Carreño JM, Wagner AL, Monahan B, Singh G, Floda D, Gonzalez-Reiche AS, Tcheou J, Raskin A, Bielak D, Morris S, Fried M, Yellin T, Sullivan L; PARIS study group; **Sordillo EM**, Gordon A, van Bakel H, Simon V, Krammer F. *SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020-2023*. Nat Commun. 2024 Jul 11;15(1):5847.doi: 10.1038/s41467-024-50052-2. PMID: 38992013.
130. Chen S, Campanella G, Elmas A, Stock A, Zeng J, Polydorides A, Schoenfeld AJ, Huang K, Houldsworth J, Vanderbilt C, Fuchs TJ. *Benchmarking embedding aggregation methods in computational pathology: a clinical data perspective [Internet]*. In: MICCAI workshop on computational pathology with multimodal data (COMPAYL). 2024. Available from: <https://openreview.net/forum?id=6E3RIPELWV>
131. Paul A and Kalir T. 2025. *The role of spirituality/religiosity in the cancer journey*. Medical Research Archives 2025; 13: 1-11.
132. Pai B, Ramos SI, Cheng WS, Joshi T, Ozen E, Mahadevan LS, Silva-Hurtado TJ, Price G, Tome-Garcia J, Nudelman G, Shroff S, Beaumont KG, Yong R, Sebra R, Zaslavsky E, **Tsankova NM**. *Spatial multi-omics defines a shared tumor infiltrative signature at the resection margin in high-grade gliomas*. **Cancer Research**, in press 2025
133. Ember K, Dallaire F, Plante A, Sheehy G, Guiot MC, Agarwal R, Yadav R, Douet A, Selb J, Tremblay JP, Dupuis A, Marple E, Urmei K, Rizea C, Harb A, McCarthy L, Schupper A, **Umphlett M, Tsankova N**, Leblond F, Hadjipanayis C, Petrecca K. *In situ brain tumor detection using a Raman spectroscopy system- results of a multicenter study*. Sci Rep 2024;14(1):13309. DOI: 10.1038/s41598-024-62543-9.
134. Kang S, Ughetta ME, Zhang JY, Marallano VJ, Sattiraju A, Hannah T, Wahane S, Ramakrishnan A, Estill M, **Tsankova NM**, Shen L, Tsankov AM, Friedel RH, Zou H. *Glioblastoma shift from bulk to infiltrative growth is guided by plexin-B2-mediated microglia alignment in invasive niches*. Nat Cancer 2025. DOI: 10.1038/s43018-025-00985-4.
135. Kim J, Poddar A, Sandoval K, Chu J, Horton E, Cui D, Nakamura K, Lu IL, Mui M, Bartels T, Wood CM, Ramos SI, Rowitch DH, **Tsankova NM**, Kim H, Sherwood CC, Kramer BW, Roberts AC, Ross PJ, Xu D, Robertson NJ, Maga

- EA, Ji P, Paredes MF. *An expanded subventricular zone supports postnatal cortical interneuron migration in gyrencephalic brains*. Nat Neurosci 2025. DOI: 10.1038/s41593-025-01987-2.
136. Mahmoudi K, Kim DH, Tavakkol E, Kihira S, Bauer A, Tsankova N, Khan F, Hormigo A, Yedavalli V, Nael K. *Multiparametric Radiogenomic Model to Predict Survival in Patients with Glioblastoma*. Cancers (Basel) 2024;16(3). DOI: 10.3390/cancers16030589.
137. Pellerin D, Del Gobbo GF, Couse M, Dolzhenko E, Nageshwaran SK, Cheung WA, Xu IRL, Dicaire MJ, Spurdens G, Matos-Rodrigues G, Stevanovski I, Scriba CK, Rebelo A, Roth V, Wandzel M, Bonnet C, Ashton C, Agarwal A, Peter C, Hasson D, **Tsankova NM**, et al. *A common flanking variant is associated with enhanced stability of the FGF14-SCA27B repeat locus*. Nat Genet 2024;56(7):1366-1370. DOI: 10.1038/s41588-024-01808-5.
138. Peter CJ, Agarwal A, Watanabe R, Kassim BS, Wang X, Lambert TY, Javidfar B, Evans V, Dawson T, Fridrikh M, Girdhar K, Roussos P, Nageshwaran SK, **Tsankova NM**, Sebra RP, Vollger MR, Stergachis AB, Hasson D, Akbarian S. *Single chromatin fiber profiling and nucleosome position mapping in the human brain*. Cell Rep Methods 2024;4(12):100911. DOI: 10.1016/j.crmeth.2024.100911.
139. Ross JL, Puigdelloses-Vallcorba M, Piñero G, Soni N, Thomason W, DeSisto J, Angione A, **Tsankova NM**, Castro MG, Schniederjan M, Wadhvani NR, Raju GP, Morgenstern P, Becher OJ, Green AL, Tsankov AM, Hambardzumyan D. *Microglia and monocyte-derived macrophages drive progression of pediatric high-grade gliomas and are transcriptionally shaped by histone mutations*. Immunity 2024;57(11):2669-2687 e6. DOI: 10.1016/j.immuni.2024.09.007.
140. Xue Y, Hou X, Zhong Y, Zhang Y, Du S, Kang DD, Wang L, Wang C, Li H, Wang S, Liu Z, Tian M, Guo K, Cao D, Deng B, McComb DW, Purisic E, Dai J, Hamon P, Brown BD, Tsankova NM, Merad M, Irvine DJ, Weiss R, Dong Y. *LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment*. Nat Commun 2025;16(1):2198. DOI: 10.1038/s41467-025-57149-2.
141. **Tripodi J**, Hoffman R, Tremblay D, Douglas Tremblay, Ahire D, Mascarenhas J, Kremyanskaya M, **Najfeld V**. *Conventional Cytogenetic Analysis and Array CGH + SNP Identify Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis Patients Who Are at Risk for Disease Progression*. Int J Mol Sci 2024 Apr 5;25(7):4061.
142. Handa S, **Tripodi J**, Schaniel C, Ahire D, Babu Mia Md, Kingborg S, Tremblay D, Marcellino B, Hoffman R, **Najfeld V**. *HMG2A overexpression with specific chromosomal abnormalities predominate in CALR and ASXL mutated Myelofibrosis*. Leukemia: 2025;39(3):663-674
143. Siegel A, **Tripodi J**, Hardatt D, Kelly B, El Ghaity-Beckley S, Becker M, Francisco B, Bailey K, **Petersen B**, Tremblay D, Feld J, Levavi H, Kremyanskaya M, Keyzner A, Marcellino BK, **Salib C**, **Duffield AS**, **Mascarenhas J**, **Najfeld V**, Shih AH. *A novel 3-way translocation involving ETV6::IL3 drives AML with eosinophilia*. Blood Neoplasia. 2025 Feb 21;2(2):100079. PMID: 40453143
144. Lo Y, Lester SC, Ellis IO, Lanjewar S, Laurini J, Patel A, Bhattacharai A, Ustun B, Harmon B, Kleer CG, Ross D, Amin A, Wang Y, Bradley R, Turashvili G, Zeng J, Baum J, Singh K, Hakima L, Harigopal M, Komforti M, Shin SJ, Abbott SE, Jaffer S, Badve SS, Khoury T, D'Alfonso TM, Ginter PS, **Collins V**, Towne W, Gan Y, Nassar A, Sahin AA, Flieder A, Aldrees R, Ngo M, Edeme U, Sapna Fnu, Schnitt SJ, Fineberg SA. *Identification of Glandular (Acinar)/Tubule Formation in Invasive Carcinoma of the Breast: A Study to Determine Concordance Using the World Health Organization Definition*. Archives of Pathology and Laboratory Medicine. 2024 Oct 1;148(10):1119-1125. DOI: 10.5858/arpa.2023-0163-OA.
145. **Heller A**, **Collins V**. Vulvar Lactating Adenoma: A Rare Representation of Mammary-Like Anogenital Glands. International Journal of Surgical Pathology. 2024 Dec 15;10668969241300532. DOI: 10.1177/10668969241300532. Epub ahead of print.
146. Slobin J, Travers G, Perez J, **Collins V**, Chen C, Port E, Marti J. *Added value of fine needle aspiration (FNA) or breast magnetic resonance imaging (MRI) as part of the "triple test" to assess palpable abnormalities on breast exam with negative imaging findings*. Annals of Surgical Oncology. Accepted for publication.
147. **Heller A**, Harigopal M, Akm JA, StClair S, **Collins V**. *TRPS1 Reliably Stains Benign and Malignant Lesions Arising Within Vulvar Anogenital Mammary-Like Glands*. International Journal of Gynecological Pathology. Accepted for publication.
148. **Richardson TE**, Orr ME, Orr TC, Ehrenberg AJ, Thorn EL, Christie TD, Yokoda RT, Marx GA, McKenzie AT, Kauffman J, Selmanovic E, Wisniewski T, Drummond E, Goate AM, Stein TD, McKee AC, White CL 3rd, Crary JF, Farrell K, Kautz TF, Daoud EV, **Walker JM**. *Hippocampal subregion-specific proteomics in chronic traumatic encephalopathy (CTE), Alzheimer's disease (AD) and primary age-related tauopathy (PART)*. Alzheimer's & Dementia. 21(2):e14487, 2025.
149. Hiya S, Maldonado-Díaz C, **Walker JM**, Richardson TE. Cognitive symptoms progress with limbic-predominant age-related TDP-43 encephalopathy stage and co-occurrence with Alzheimer disease. J Neuropathol Exp Neurol. 83(1):2-10, 2024.
150. Chapleau M, La Joie R, Yong K, Agosta F, Allen IE, Apostolova L, Best J, Boon BDC, Crutch S, Filippi M, Fumagalli GG, Galimberti D, Graff-Radford J, Grinberg LT, Irwin DJ, Josephs KA, ...Tanner J, **Walker JM**, Jennifer L Whitwell, Wolk DA, Ossenkoppele R, Rabinovici GD. *Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis*. Lancet Neurol. 23(2):168-77, 2024.
151. An J, Hu E, Shi Y, Fang Y, Liu N, Liu Q, Wang Q, Wang Y, He W, Wang A, Song Y, Shan J, Zhang J, Zou Y, Cheng H, Kabarriti R, **Cai W**, Verma A, Sica RA, Deng W, Yin S. *Single-cell analysis of oncolytic virotherapy in adult T-cell leukemia/lymphoma*. J Immunother Cancer 2025;13: e011265. DOI: 10.1136/jitc-2024-011265. PMID: 40132906
152. Wang X, De Moll E, Koschitzky M, Shihab N, Khattri S, **Phelps R**. *Clinically amyopathic dermatomyositis: Clinical, laboratory, and histopathological features*. J Cutan Pathol. 2024 Oct;51(10):799-806. doi: 10.1111/cup.14691. Epub 2024 Jul 15. PMID: 39005210.
153. Liao X, Schmidt AL, Zhang D, Li P, Wang X, Ko HM, Choi WT, Alpert L, Hao Y, Kovar-Peltz S, Polydorides AD, Wanjar P, Mastro J, Wang P. *Clinicopathologic and Molecular Characterization of Inflammatory Bowel Disease-Associated Neuroendocrine Carcinomas and Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms*. Mod Pathol 2024 Jul 16:100566.
154. **Kombak FE**, **Liu Q**, **Paulsen JD Jr**, **Wang X**, **Amlashi FG**, **Hui P**, **Zheng W**, **Polydorides AD**, **Liu Y**. *Challenges in Consistent Histologic Diagnosis of Superficially Invasive Anal Squamous Cell Carcinoma*. Arch Pathol Lab Med. 2025 Jul 10. doi: 10.5858/arpa.2024-0463-OA. Epub ahead of print. PMID: 40635196.
155. Liu Y, Bhardwaj S, Sigel K, Winters J, Terlizzi J, Gaisa MM. *Anal cancer screening results from 18-to-34-year-old men who have sex with men living with HIV*. Int J Cancer. 2024;154:21-27.
156. Stier EA, Clarke MA, Deshmukh AA, Wentzensen N, **Liu Y**, Poynter IM, Cavallari EN, Fink V, Barroso LF, Clifford GM, Cuming T, Goldstone SE, Hillman RJ, Rosa-Cunha I, La Rosa L, Palefsky JM, Plotzker R, Roberts JM, Jay N. *International Anal Neoplasia Society's consensus guidelines for anal cancer screening*. Int J Cancer. 2024;154:1694-1702.
157. Mutetwa T, **Liu Y**, Silvera R, Evans M, Yurich M, **Tripodi J**, **Leonard I**, **Houldsworth J**, **Gümüş Z**, Bowcock AM, Sigel K, Gaisa M, Polak P. *Host Nuclear Genome Copy Number Variations Identify High-Risk Anal Precancers in People Living With HIV*. J Acquir Immune Defic Syndr. 2024;96:190-195.
158. Gaisa M, Deshmukh A, Sigel K, **Liu Y**. 2024 *Anal Cancer Screening Guidelines: Analysis of Clinical Performance and HRA Utilization in a large Cohort of Persons with HIV*. Clin Infect Dis. 2025 Feb 3. Epub ahead of print. PMID: 39899367.
159. Deshmukh AA, Damgacioglu H, Sigel K, Palefsky JM, Clarke MA, Wentzensen N, Nyitray AG, Ortiz AP, Lin YY, Chiao EY, Stier E, Jay N, Gaisa M, **Liu Y**, Meissner EG, Lazenby G, Giuliano AR, Goldstone SE, Clifford GM, Sonawane K, Chhatwal J. *Screening for Anal Cancer Among Men Who Have Sex With Men With HIV: Benefits, Harms, and Cost-Effectiveness Analyses*. Ann Intern Med. 2025 Jun 17. PMID: 40523287.
160. Varma M, Amin MB, Berney DM, Compérat E, Epstein JI, Iczkowski KA, Kristiansen G, Paner GP, Shah RB, Shaw G, van der Kwast TH, van Leenders GJ, **Zhou M**, Williamson SR. *Histological sampling protocols for transurethral*

- resection of prostate specimens need reappraisal*. Histopathology. 2024 Nov;85(5):746-747. Epub 2024 Sep 10.
161. Shah RB, Paner GP, Cheng L, De Marzo AM, Magi-Galluzzi C, Varma M, Zhou M, Amin A, Amin MB, Aron M, et al. *Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: Call for a Multidisciplinary Approach*. Eur Urol. 2025 Mar 17;S0302-2838(25)00150-2. doi: 10.1016/j.eururo.2025.02.029. PMID: 40102113
 162. Varma M, Kristiansen G, Paner GP, Zhou M. *Reporting Prostatic Atypical Intraductal Proliferations: Call for a Different Approach*. Am J Surg Pathol. 2025 Jun 12;49(8):854. doi: 10.1097/PAS.0000000000002437. PMID: 40509711
 163. Mohanty SK, Lobo A, Jha S, Sangoi AR, Akgul M, Trpkov K, Hes O, Mehra R, Hirsch MS, Moch H, Smith SC, Shah RB, Cheng L, ... Zhou M, Sable M, et al.. *Acceptance of emerging renal oncocytic neoplasms: a survey of urologic pathologists*. Virchows Arch. 2024 Nov;485(5):829-840. doi: 10.1007/s00428-024-03909-2. Epub 2024 Sep 17.
 164. Lobo A, Collins K, Kaushal S, Acosta AM, Akgul M, Adhya AK, Al-Ahmadie HA, Al-Obaidy KI, Amin A, Amin MB, Aron M, Balzer BL, Biswal R, Mohanty S, Browning L, ... Muñiz Unamunzaga G, Zhou M, Williamson SR, Lopez-Beltran A, Cheng L, Mohanty SK. *Advances, recognition, and interpretation of molecular heterogeneity among conventional and subtype histology of urothelial carcinoma (UC): a survey among urologic pathologists and comprehensive review of the literature*. Histopathology. 2024 Nov;85(5):748-759. doi: 10.1111/his.15287. Epub 2024 Jul 29.]
 165. Tanwar H, Gnanasekaran JM, Allison D, Chuang LS, He X, Aimetti M, Baima G, Costalonga M, Cross RK, Sears C, Mehndru S, Cho J, Colombel JF, Raufman JP, Thumbigere-Math V. *Unravelling the Oral-Gut Axis: Interconnection Between Periodontitis and Inflammatory Bowel Disease, Current Challenges, and Future Perspective*. J Crohns Colitis. 2024 Aug 14;18(8):1319-1341. doi: 10.1093/ecco-jcc/jjae028. PMID: 38417137 Free PMC article. Review.
 166. Hernández-Rocha C, Turpin W, Borowski K, Stempak JM, Sabic K, Gettler K, Duerr RH, Schumm LP... Cho JH, Silverberg MS. *After Surgically Induced Remission, Ileal and Colonic Mucosa-Associated Microbiota Predicts Crohn's Disease Recurrence*. Clin Gastroenterol Hepatol. 2025 Mar;23(4):612-620.e10. PMID: 38969076
 167. Jacobs JP, Spencer EA, Helmus DS, Yang JC, Lagishetty V, Bongers G, Britton G, Gettler K, Reyes-Mercedes P, Hu J, Hart A, Lamoué-Smith E, Wehkamp J, Landers C, Debbas P, Torres J, Colombel JF, Cho J, Peter I, Faith J, Braun J, Dubinsky M. *Age-related patterns of microbial dysbiosis in multiplex inflammatory bowel disease families*. Gut. 2024 Nov 11;73(12):1953-1964. PMID: 39122361
 168. Bloemen H, Livanos AE, Martins A, Dean R, Bravo AC, Bourgonje AR, Tankelevich M, Herb J, Cho J, Santos AA, Rodrigues CMP, Petralia F, Colombel JF, Bowlus CL, Schiano T, Torres J, Levy C, Mehndru S. *Anti-integrin α v β 6 Autoantibodies Are Increased in Primary Sclerosing Cholangitis Patients With Concomitant Inflammatory Bowel Disease and Correlate With Liver Disease Severity*. Clin Gastroenterol Hepatol. 2025 Aug;23(9):1612-1622.e8. PMID: 39490950
 169. Ibing S, Hugo J, Borchert F, Schmidt L, Benson C, Marshall AA, Chasteau C, Korie U, Paguay D, Sachs JP, Renard BY, Cho JH, Böttlinger EP, Ungaro RC. *Electronic Health Records-based identification of newly diagnosed Crohn's Disease cases*. Artif Intell Med. 2025 Jan;159:103032. doi: 10.1016/j.artmed.2024.103032. Epub 2024 Nov 21. PMID: 39591878
 170. Petrazzini BO, Balick DJ, Forrest IS, Cho J, Rocheleau G, Jordan DM, Do R. *Ensemble and consensus approaches to prediction of recessive inheritance for missense variants in human disease*. Cell Rep Methods. 2024 Dec 16;4(12):100914. doi: 10.1016/j.crmeth.2024.100914. Epub 2024 Dec 9. PMID: 39657681
 171. Gibson G, Rioux JD, Cho JH, Haritunians T, Thoutam A, Abreu MT, Brant SR, Kugathasan S, McCauley JL, Silverberg M, McGovern D. *Eleven Grand Challenges for Inflammatory Bowel Disease Genetics and Genomics*. Inflamm Bowel Dis. 2025 Jan 6;31(1):272-284. doi: 10.1093/ibd/izae269.
 172. Guisado D, Talware S, Wang X, Davis A, Fozilov E, Etra A, Colombel JF, Schaniel C, Tastad C, Levine JE, Ferrara JLM, Ling-Shiang C, Sabic K, Singh S, Marcellino BK, Hoffman R, Cho J, Cohen L. *Reparative immunological consequences of stem cell transplantation as a cellular therapy for refractory Crohn's disease*. Gut. 2025 May 7;74(6):894-905. PMID: 39961646.
 173. Choi JH, Thung SN. *Pathology and diagnostic approaches to well-differentiated hepatocellular lesions: a narrative review*. J Yeungnam Med Sci. 2025;42:5. doi: 10.12701/jyms.2024.00766. Epub 2024 Oct 24. PMID: 39442859
 174. Piqué-Gili M, Andreu-Oller C, Mesropian A, Esteban-Fabro R, ... Dekervel J, Thung SN, Sia D, Lujambio A, Pinyol R, Llovet JM. *Oncogenic role of PMP2A1 and its association with immune exhaustion and TGF- β activation in HCC*. JHEP Rep. 2024 Sep 7;6:101212. PMID: 39524206
 175. Choi JH, Thung SN. *Mesenchymal Tumors of the Liver: An Update Review*. Biomedicines. 2025 Feb 15;13(2):479. doi: 10.3390/biomedicines13020479. PMID: 40002892. Review.
 176. Bane O, Geahchan A, Stocker D, Pavuluri S, Abboud G, Kennedy P, Sharma H, Hectors SJ, Thung S, Jin N, Fischman A, Markl M, Reeder S, Schiano TD, Taouli B. *Splanchnic hemodynamic parameters measured with 4D flow MRI can diagnose severe portal hypertension*. Eur Radiol. 2025 Jul 15. doi: 10.1007/s00330-025-11799-4. Online ahead of print. PMID: 40664866

Books and Book Chapters

- Baine I and Arinsburg SA. "Granulocytes." In *Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects*. Ed. Shaz BH, Hillyer CD, Schwartz J, Morayma G. 4th ed. Burlington, MA: Elsevier; 2024.
- Arinsburg SA and Baine I. "Antibody Identification." In *Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects*. Ed. Shaz BH, Hillyer CD, Schwartz J, Morayma G. 4th ed. Burlington, MA: Elsevier; 2024.
- Baine I and Arinsburg, SA. "Pretransfusion Testing." In *Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects*. Ed. Shaz BH, Hillyer CD, Schwartz J, Morayma G. 4th ed. Burlington, MA: Elsevier; 2024.
- Baine I and Arinsburg, SA. "Transfusion of Patients Undergoing Hematopoietic Stem Cell Transplant." In *Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects*. Ed. Shaz BH, Hillyer CD, Schwartz J, Morayma G. 4th ed. Burlington, MA: Elsevier; 2024.
- Arinsburg SA. Section ed. Immunology and HLA. In *Clinical Pathology Board Review*. Eds Arinsburg SA and Jhang JS. 2nd Ed. Philadelphia: Elsevier; 2025.
- Paniz-Mondolfi AE, Salas RA, de Manzione N, Delgado-Noguera LA, Valderrama-Rodriguez O, Escalona-Rodriguez M, Márquez-Colmenarez M, Luna N, Chace A, Sordillo EM, Ramirez JD. Phylogenetics, Eco-epidemiology, and Evolution of Orthohantaviruses in Venezuela. In: Pujol FH, Paniz-Mondolfi AE, editors. *Emerging Viruses in Latin America*. Contemporary Virology . Springer Nature. 2024. P. 61-84
- Liu, Y., Zheng, W. (2024). Cervical Cancer Development, Screening, and Prevention. In: Zheng, W., Fadare, O., Quick, C.M. editor. *Gynecologic and Obstetric Pathology*. Springer, Singapore. p.1-16.
- Arinsburg SA and Jhang JS, Eds. *Clinical Pathology Board Review*. 2nd Ed. Philadelphia: Elsevier, 2025.
- Camelia Iancu-Rubin and Rona Weinberg: Chapter 92, Overview of Cellular Therapy and Chapter 93, Hematopoietic Progenitor Cells Products Derived from Bone Marrow and Peripheral Blood, in "Transfusion Medicine and Hemostasis", Fourth Edition, 2024. Elsevier; Editors: Shaz, Hillyer, Schwartz and Reyes Gill.
- Camelia Iancu-Rubin and Rona Weinberg: Chapter 93, Hematopoietic Progenitor Cells Products Derived from Bone Marrow and Peripheral Blood, in "Transfusion Medicine and Hemostasis", Fourth Edition, 2024. Elsevier; Editors: Shaz, Hillyer, Schwartz and Reyes Gill.

Digital Publications

- Rastegar S., Kalir T. Leydig cell hyperplasia. Pathology Outlines.com website. 2025. <https://www.pathologyoutlines.com/topic/ovaryleydigcellhyperplasia.html>
- Nishikawa Y., Kalir T. Ovarian torsion. Pathology Outlines.com.website.2025 <https://www.pathologyoutlines.com/topic/ovarytubetorsion.html>

Grants awarded in 2024-2025 academic year

Faculty	Agency	Title
Nadejda Tsankova, MD, PhD	NINDS / NIH / IDHHS	Harnessing YAP-TEAD activity as anti-invasion therapeutic in human glioblastoma.
	NINDS / NIH	Myeloid recruitments and their role in brain tumors
	NINDS / NYU	Inducing neural maturation in medulloblastoma by targeting EZH2
Stephen Ward, MD, PhD	National Institute Of Allergy And Infectious Diseases/NIH/DHHS	Genomic and environmental drivers of HCC in Non-Hispanic Blacks: Nature and nurture
Yuxin Liu, MD, PhD	NCI	Comprehensive molecular and immunologic characterization of anal carcinogenesis in men and women living with HIV
	NIH	The Effectiveness of High-Resolution Microendoscopy in anal HSIL Diagnosis for People Living with HIV
Rachel Brody, MD, PhD	Regeneron Pharmaceuticals, Inc.	A LAG-3 and FGL1 expression in NSCLC
	NCI/NIH	Defining and overcoming lineage plasticity in lung cancer
	NCI/NIH	Targeting ferroptosis in aggressive subtypes of lung cancer
	NCI/NIH	Multi-scale analysis of Bacillus Calmette-Guérin (BCG) resistant tumor micro-environment in non-muscle invasive bladder cancer to identify novel therapeutic axis
John Crary, MD, PhD	National Institute Of Neurological Disorders And Stroke/NIH/DHHS	Investigating mechanisms of neurological post-acute sequelae of SARS CoV2 using quantitative multiparametric in-vivo and ex-vivo MRI
Kurt Farrell, PhD		Identifying TDP-43 pathology burden in a mixed cohort of aging brains
Karen Edelblum, PhD	NIDDK	CD39 in gd intraepithelial lymphocyte function

Active grants

Faculty	Agency	Title
Margaret Brandwein, MD	CDC/NIOSH	The effect of WTC exposure on thyroid cancer in the survivor population
Mary Beth Beasley, MD	NCI/NIH/DHHS	Investigating macrophage molecular and functional diversity in tumor immunity
	NIH/Duke University	Senescent cell evaluations in normal tissues (SCENT) mapping center
Qingqing Liu, MD, PhD	The Foundation for the National Institutes of Health	Mucosal healing for ulcerative colitis
Nadejda Tsankova, MD, PhD	NINDS / NIH	Plexin-B2 function in glioma invasion
	NCI / NIH	The role of myeloid cells in pediatric-high grade gliomas
	NIH / NINDS	Tumor-associated macrophages in vasogenic cerebral edema in brain tumors
	NINDS / NYU	Inducing neural maturation in medulloblastoma by targeting EZH2
Yuxin Liu, MD, PhD	NIH	The effectiveness of screening women with lower genital tract neoplasia or cancers for anal cancer precursors
Shafinaz Hussein, MD	NIH / NCI	From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma
Emilia Sordillo, MD, PhD	National Institute Of Allergy And Infectious Diseases/NIH/DHHS	Dissecting the drivers of persistent SARS-CoV-2 infections
	Global Influenza Hospital Surveillance Network	Mount Sinai Respiratory Viral Pathogens Surveillance Program
Karen Edelblum, PhD	NIDDK	Interferon regulation of gamma delta intraepithelial lymphocyte activation
	NIAID	Microbiota-gd IEL-Paneth cell axis in host antimicrobial response
	Crohn's and Colitis Foundation	$\gamma\delta$ T cells in Crohn's disease
	NIAID/ Rutgers University	CD103 engagement regulates intestinal IEL function
	NIDDK	gd IELs in chronic ileitis

Invited Talks

Brett Baskovich, MD	Cancer Data Champions: Synoptic Reporting for Tissue Imaging Biomarkers. CAP Webinar, Alex Baras, MD, PhD, Brett Baskovich, MD. Nov 2024.
Mary Beth Beasley, MD	Invited Speaker: Precision in Practice: Essential Strategies for Genomic Testing in NSCLC. USCAP annual meeting, Boston, MA March 25, 2025.
	Invited participant: LUNGevery Precision Medicine Initiative Summit: Progress report, reflex testing hospital and health system working group update. March 26, 2025 Washington, DC.
	Invited panelist: Invited Pathology Grand Rounds Speaker: MGB/Harvard Health Systems. Topic: Acute Lung injury: Diagnostic Approach and Lessons Learned Since 2020. February 13, 2025. Boston, MA
	Advances in Pulmonary Medicine Icahn School of Medicine at Mount Sinai/National Jewish Respiratory Institute November 8 2024 Topic: Challenging cases in interstitial lung disease—the importance of multidisciplinary discussion. New York, New York
	Invited panelist: 14 th Conference on Early Lung Cancer Research on Treatment, September 21, 2024. Topics: Defining recurrence and options for treatment; Consideration for Updating Staging and Treatment for Early Stage Lung Cancer. New York, New York.
	Invited speaker: Pulmonary pathology of systemic diseases including vasculitis and IgG4-related disease. MSKCC/MGH Thoracic Pathology Course; September 14, 2024. Virtual.
	Invited speaker: The Pathologist's Approach to Acute Lung Injury. MSKCC/MGH Thoracic Pathology Course; September 14, 2024.
Chunli Yu, MD	Session chair: Biomarkers for Lung Cancer in 2024. IASLC World Conference on Lung Cancer, September 9, 2024, San Diego, CA
	Validation and Approval Process of Laboratory Developed Tests (LDT) in New York State-Example of Biochemical Genetic Testing" Baylor Genetics Department, September 12, 2024
Karen Edelbaum, PhD	$\gamma\delta$ IEL regulation of the intestinal barrier. Vanderbilt Digestive Disease Research Center Seminar Series. Nashville, TN. October 8, 2024.
	$\gamma\delta$ IEL regulation of the intestinal barrier. Emory Digestive Disease Initiative Seminar Series. Atlanta, GA. November 14, 2024.
	$\gamma\delta$ IEL regulation of the intestinal barrier. Center for Discovery and Innovation Seminar Series, Hackensack Meridian Health. Hackensack, NJ. December 10, 2024.
	$\gamma\delta$ IEL regulation of the intestinal barrier. Department of Microbiology Seminar Series, University of Pennsylvania. Philadelphia, PA. January 15, 2025.
	Commensal microbiota promote $\gamma\delta$ IEL regulatory function. Banff Inflammation Workshop, Banff, Alberta, Canada. January 24, 2025.
	$\gamma\delta$ IEL regulation of the intestinal barrier. Department of Microbiology & Immunology Seminar Series, Thomas Jefferson University. Philadelphia, PA. March 19, 2025.
Isabel Fiel, MD	"Late liver allograft dysfunction". Laennec Annual Meeting, Milan, Italy. May 23, 2025
	"Challenges in Long-Term Allograft Liver Dysfunction: Role of Antibody-Mediated Rejection". Grand Rounds, Houston Methodist, Houston, TX, May 6, 2025.
	"Unusual and Rare Liver Tumors". International Liver Study Group (Gnomes) 2025 Meeting, Brisbane, Australia, April 24, 2025.
	"Biliary tract disorders across the lifespan: Key entities in children and adults". USCAP 114 th Annual Meeting, Boston, MA. March 21, 2025.
	"COVID Hepatopathy: What we have learned". International Academy of Pathology, Cancun, Mexico. October 29, 2024.
	"Chasing our tail: Are we over-diagnosing and over-treating low-grade rejection following intestinal transplantation?". American Transplant Congress, Philadelphia, PA, June 1-4, 2024.
	"The Evolution of Plasma Cell-Rich Rejection". Laennec Annual Meeting, Fukuoka 2024, May 15-17, 2024
	"Cholangiocarcinoma: An Update on Genetic Drivers and Their Impact on Clinical Management" Grand Rounds Harbor-UCLA Medical Center, Los Angeles, CA, January 5, 2024
Noam Harpaz, MD, PhD	Nonconventional dysplasia in IBD: histopathologic criteria, classification and implications. Digestive Disease Week, San Diego, CA. May 6, 2025
Kurt Farrell, PhD	Pathology at the Core: Enhancing Translational Research in Neurodegenerative Diseases. Mount Sinai Pathology research day New York, NY, May 27th, 2025
	Genetic risk in PSP in different populations. Tau Global Conference, London England, April 25, 2025

Margaret Brandwein, MD	Macroscopy Under the Microscope, Webinar, Cardiff UK ‘Head and Neck Margin Mapping: Shifting the Paradigm of Surgeon/Pathologist Conversations – 3D Specimen Representations.
Melissa Umphlett, MD	“cIMPACT-NOW Update: Molecular risk parameters and recommendations for meningiomas” Neuro-oncology Conference. The Valley Hospital, Paramus, New Jersey June 2, 2025
Shafinaz Hussein, MD	Invited Panelist: Idiopathic Multicentric Castleman Disease (iMCD), Plan of Action, Recordati Rare Diseases. New York, NY July 2025.
Ming Zhou, MD, PhD	Should We Keep Calling Grade Group 1 Prostate Cancer? A Pathology Community Perspective. 7th International Prostate Cancer Symposium and World Urologic Oncology Symposium, New York, NY, December 11-14, 2024
	Contemporary Update on Prostate Cancer Grading. International Congress on Frontiers in Urologic Oncology and Uropathology. Bhubaneswar, Odisha, India. January 10-12, 2025
	Ductal adenocarcinoma of the prostate. International Congress on Frontiers in Urologic Oncology and Uropathology. Bhubaneswar, Odisha, India. January 10-12, 2025
	New and recently described pink cell tumors of the kidney and judicious use of immunohistochemistry for work-up. 35 th Annual Meeting of the Royal Society of Pathologists of Thailand. Bangkok, Thailand, February 26-28, 2025. (Virtual)
	Prostate Cancer Pathology 2025. 2 nd Surgical Pathology and Cytopathology Summit. Dubai, UAE, April 12 th , 2025.
	Diagnoses of the Testicular Tumors that You Want to Get Right: A Case-based Tutorial. 2nd Surgical Pathology and Cytopathology Summit. Dubai, UAE, April 12 th , 2025.
	Optimizing Immunohistochemistry and Molecular Testing in Urothelial Carcinomas: A Practical Guide for Surgical Pathologists. 2nd Surgical Pathology and Cytopathology Summit. Dubai, UAE, April 12 th , 2025.
	Prostate Cancer Pathology 2024. The Ohio State University Department of Pathology Update Course. Columbus, OH, October 10-11, 2024.
	Pathology of the Testicular Germ Cell Tumors: An Update. The Ohio State University Department of Pathology Update Course. Columbus, OH, October 10-11, 2024.
	Fifty Shades of Pink: New and Recently Described Oncocytic Tumors of the Kidney. California Society of Pathologists – CSP 2024 Annual Meeting: Seminars in Pathology, San Francisco, CA, 12/03-07/2024
	Pattern based Diagnosis and Classification of Renal Tumors. California Society of Pathologists – CSP 2024 Annual Meeting: Seminars in Pathology, San Francisco, CA, 12/03-07/2024
	Prostate Cancer Pathology 2025. Florida Society of Pathologists 2025 Annual Pathology Conference, Orlando, FL, February 14-16, 2025
John D. Paulsen, MD	“Pearls in the Diagnosis of Lower GI Tract Infections” Southern California Permanente Medical Group (SCPMG). Anatomic Pathology Diagnostic Mastery Series. Los Angeles, California, USA. October 1, 2024
	“Collagenous Colitis and Collagenous Gastritis: Exploring Their Shared and Distinct Pathogeneses”, Department of Pathology at Montefiore Medical Center, Bronx, NY. June 2024
Qingqing Liu, MD, PhD	Grand Rounds, Baylor Pathology Citywide Grand Rounds, Department of Pathology & Immunology at Baylor College of Medicine, Houston, TX, April 2025.
Timothy Richardson, DO, PhD	“Factors Underlying Rapid Progression and Resilience in Patients with High-Level ADNC” American Association of Neuropathologists, Minneapolis, MN, USA. June 20, 2025
Aryeh Stock, MD	“The Latest on Histological Diagnosis of EoE and non-EoE EGIDs”
	EoExcellence (Mount Sinai Center for Eosinophilic Disorders) Multidisciplinary Advances and Personalized Strategies for the Management of EoE and other Eosinophilic Gastrointestinal Disorders. New York, NY, USA. June 30, 2025

Nadejda Tsankova, MD, PhD	NYC-NCI Postdoctoral Symposium “Biology of <i>glioblastoma invasion</i> : A Single-Cell Level Analysis of Core vs. Infiltrating Edge” (oral presentation selection, senior author)
	TCI Cancer Mechanisms, “Dynamics of Glioblastoma Infiltration: Spatial Multi-Omics Analysis from Core to Margin”, April 3, 2025 (invited lecturer)
Jaime Walker, MD, PhD	Plasma biomarker and spatial proteomic studies of mixed pathology cases. AANP 2025: Platform Presentation. Minneapolis, MN
	Spatial proteomic comparison of the hippocampi in AD, PART, and CTE. Tau 2024 International Conference. Washington, DC
	Spatial proteomic differences between AD, PART, and CTE in the hippocampus. AD/PD 2024. Lisbon, Portugal
Stephen Ward MD, PhD	Inclusions in Hepatocellular Carcinoma. Laennec Liver Pathology Society Annual Meeting, Milan, Italy, May 22, 2025.
Yuxin Liu, MD, PhD	Europe Anal Cancer Screening Taskforce: SISCCA from a pathology perspective. September 2024, Webinar.
	Anogenital Squamous Cell Carcinoma: Updated Screening Guidelines and Diagnostic Challenges. Yale School of Medicine, Department of Pathology. November 2024, Webinar.
	Anogenital Squamous Cell Carcinoma: Updated Screening Guidelines and Diagnostic Challenges. New York University, Department of Pathology, New York, NY, January 2025.
	Multizonal anogenital neoplasia in women with genital precancer and cancer: baseline findings from a prospective clinical trial. EUROGIN INTERNATIONAL MULTIDISCIPLINARY HPV CONGRESS, Porto, Portugal, March 2025.
	Implementation Essentials: Anal cancer screening referral Algorithm, HRA Clinic Setup, and Surveillance. Enhancing Diagnostic Excellence: Collaboration with Cytologists and Pathologists. American Society for Colposcopy and Cervical Pathology Annual Scientific Meeting (ASCCP). April 2025, San Diego, CA,
	International Anal Neoplasia Society (IANS): Atypical non-SCC anal cancers. May 2025, Webinar.
	High-resolution anoscopy Clinical Workshop: Involving Referring Providers and Pathology in Your HRA Service. June 2025, London, UK.
	Challenges in Consistent Histological Diagnosis of Superficially Invasive Anal Squamous Cell Carcinoma. June 2025, London, UK, International Anal Neoplasia Society (IANS) Annual Scientific Meeting

Awards

Carlos Cordon-Cardo, MD, PhD	ScholarGPS Highly Ranked Scholars™ – Placed in the top 0.05% of all scholars worldwide (over 200 countries and over 30 million academic, industrial, and government scholars)
	Member, Sigma Xi, The Scientific Research Honor Society
	“Premio Latido de Excelencia de Medicina Responsable,” Madrid, Spain.
Kurt Farrell, PhD	Publication of the year, from the Alzheimer’s Association and The Frontotemporal Dementia and Related Disorders interest group. Publication title “Genetic, transcriptomic, histological, and biochemical analysis of progressive supranuclear palsy implicates glial activation and novel risk genes”

Recognition

Heather Reiss, MBA	Hard working Pathology staff received the “Beyond the Badge” recognition from the Mount Sinai Health System. <i>Beyond the Badge</i> is a recognition event created to further acknowledge and celebrate the hard working employees.
AKM Juber Ahmed	
Atufah Shah	
Maria Theresa Alcantara	
Samantha StClair	

MEET THE NEW FACULTY



Nabeel Borazan, MD

Dr. Nabeel Borazan began his medical journey by earning an MD degree from the University of Baghdad, College of Medicine in 2003. In 2018, he earned a second MD from Xavier University School of Medicine in Aruba. He completed his AP/CP residency at Mount Sinai West/Morningside, followed by a Fellowship in Liver Pathology at Mount Sinai Hospital. Now working as an attending pathologist with a focus on Liver and Gastrointestinal Pathology, Dr. Borazan combines his diagnostic expertise with a strong commitment to education and collaboration. His decision to specialize in liver pathology stemmed from a deep interest in the intersection of histopathology and clinical medicine—an area where each case is a complex puzzle involving both microscopic detail and patient-centered context. He is passionate about supporting clinicians in understanding disease processes and guiding optimal treatment strategies. Dr. Borazan credits the exceptional training and mentorship he received at Mount Sinai for shaping his practice and reinforcing his commitment to academic medicine. Outside the microscope, Dr. Borazan enjoys photography and art; he is also captivated by Mesopotamian history. At home, he proudly holds the title of “Dinosaur, Lego and Peppa Pig expert,” a distinction earned thanks to his three-year-old son.



Quintus Chess, MD

Dr. Chess did his AP only residency at New York Presbyterian-Weill Cornell and his Fellowship in Cytopathology at Memorial Sloan-Kettering Cancer Center. He joins our department as Associate Professor in Pathology and Co-Director of the FNA (fine needle aspiration) biopsy clinic at Union Square, where they are “interventional cytologists.” For many years, Dr. Chess has focused on FNA and that is his main interest in Pathology. Dr. Chess is a particularly strong advocate for ROSE (rapid on-site evaluation) for FNA and anticipates its digitalization and tele-cytology applications. A favorite Cytology aphorism that Dr. Chess wants to close with is the following from Rudolf Virchow: “Omni Cellula e cellula.”



Ritu Gupta, MD

Before heading up to the Northeast, Dr. Ritu Gupta was in a much sunnier climate for medical school, earning her MD from University of Miami Miller School of Medicine. She then decided the Northeast was the perfect place to do her GME training, completing her AP/CP residency at Montefiore Medical Center, her Renal Pathology Fellowship at Brigham and Women’s Hospital, and her GU Pathology Fellowship at Johns Hopkins Hospital. Moving back to New York City, Dr. Gupta is now part of our Department as Assistant Professor of Pathology, Renal and Genitourinary Pathologist, the Residency Rotation Director for Renal Pathology, and the Associate Program Director for the Renal Pathology Fellowship. Dr. Gupta is most interested in studying glomerular disease pathophysiology and the interplay of renal neoplastic disease and medical renal disease. She is also actively interested in Undergraduate and Graduate Pathology education. When not busy signing out cases, Dr. Gupta pursues plenty of hobbies, including hiking, paddle boarding, going to concerts/festivals/comedy shows, and spending time with family & friends. Dr. Gupta isn’t just interested in watching concerts; she also played music with classmates at charity events, the equivalent of the “white coat ceremony,” and a medical student conference during medical school.



Syed Hoda, MD

Dr. Syed Hoda joins the Department as Clinical Professor and Attending Pathologist in the Breast Service. He is a graduate of Dow Medical College. Following medical school and moving to the U.S., Dr. Hoda underwent anatomic and clinical pathology residency training at Tulane University Hospitals in New Orleans and fellowship training in oncological surgical pathology as well as cytopathology at Memorial Sloan Kettering Cancer Center. Following his Fellowship training, he joined New York Hospital-Cornell Medical Center (now New York Presbyterian Hospital-Weill Cornell Medical Center) as Assistant Professor, and over the years, he attained the rank of Professor. Dr. Hoda has an abiding interest in breast pathology, and has published extensively on the topic. He was the lead author of the last several editions of *Rosen’s Breast Pathology* and *Rosen’s Diagnosis of Breast Pathology by Needle Core Biopsy*. Outside of work, Dr. Hoda likes to draw, paint, and indulge in calligraphy.



Sonali Lanjewar, MD

While currently working at Montefiore Medical Center as Assistant Professor of Pathology and Director of Gynecologic Pathology, we’re also fortunate to have Dr. Sonali Lanjewar working in our department in a remote only position as Associate Clinical Professor for the Breast Service. Dr. Lanjewar went to medical school at Grant Medical College in Mumbai, India. After medical school and moving to the U.S., Dr. Lanjewar did her residency at SUNY Health Science Center in Brooklyn and her Fellowship in Women’s Health Pathology at Montefiore Medical Center. Dr. Lanjewar’s main area of research is focused on chemotherapy-treated breast carcinoma. Outside of work, Dr. Lanjewar is a trained Indian classical dancer and enjoys practicing it regularly and absolutely loves playing tennis. Dr. Lanjewar also enjoys the pursuit of knowledge, learning a new skill every year since fellowship. This has led to her learning about pottery, knitting, and learning ballroom dancing at the Fred Astaire Dance Center. This year, the skill that Dr. Lanjewar is reading about is the basics of finance.



Aryeh Stock, MD

For those keeping track, this is the third year in a row that Dr. Stock is being introduced in this newsletter. Dr. Stock’s relationship with Mount Sinai began on his birthday in the Kravis Children’s Hospital. In the intervening years he attended the Icahn School of Medicine at Mount Sinai, completed his residency at the Mount Sinai Hospital, worked as an Instructor in our division of Autopsy, and completed his fellowship in GI Pathology at the Mount Sinai Hospital. Dr. Stock now rejoins our faculty as an Assistant Professor for the divisions of Gastrointestinal Pathology and Autopsy and will be continuing his research in Computational Pathology and AI. Fun fact: In spite of the overwhelming evidence, Dr. Stock is not the eponym for Stockholm syndrome.

MEET THE NEW FACULTY



Ming Zhou, MD, PhD

Dr. Ming Zhou has come to Mount Sinai with a very illustrious pedigree. Initially, Dr. Zhou went to medical school at Fudan University of Medicine in Shanghai, China. After medical school, Dr. Zhou moved to the U.S. to do his Pathology Residency at the University of Michigan in Ann Arbor and his Fellowship in Surgical Pathology at Johns Hopkins Hospital. Post training, Dr. Zhou was a member of the USCAP Board of Directors from 2021-2024 and has also served as the President of the Genitourinary Pathology Society (GUPS). Dr. Zhou also authored over 200 peer-reviewed articles, 120 review articles and book chapters, and also co-edited 8 textbooks on urological and prostate pathology. Thus, it's a great privilege to have had Dr. Zhou join our department in 2024 in the roles as Professor of Pathology, Vice Chair for Oncological Pathology, and Director of the Genitourinary Pathology Service and Fellowship. Dr. Zhou's research interests focus on diagnostic urological pathology and the discovery and validation of tumor markers for urological malignancy. Outside of academia, Dr. Zhou is an avid tennis player and loves to travel.



Allen Leung, MD

Dr. Allen Leung joins our department as Clinical Assistant Professor in Cytopathology. Dr. Leung went to medical school at Stony Brook University and did his residency training at Montefiore Medical Center. After Residency, Dr. Leung did three fellowships: Surgical Pathology at University of New Mexico, Cytopathology at SUNY Upstate, and Bone/Soft Tissue at NYU. Academically, Dr. Leung is focused on all things cytopathology and FNA. Outside of work, Dr. Leung is interested in staying updated on new technology trends. Whenever Dr. Leung tires of being in the Northeast, he takes the time to visit Florida often and enjoys the sunshine there.



Elisabet Pujadas, MD, PhD

It is a great honor that one of our recent alums of our Residency Program, Dr. Elisabet Pujadas, has returned to the Department to join us as Assistant Professor based in our Head and Neck Pathology division. A graduate of Johns Hopkins School of Medicine, Dr. Pujadas came to Mount Sinai for an AP Only PSTEP Residency. After graduating from Residency, Dr. Pujadas went to Memorial Sloan Kettering Cancer Center for two fellowships, Oncologic Surgical Pathology and Molecular Genetic Pathology. Dr. Pujadas' many research interests include spatial transcriptomics, epigenetics, technology development in molecular pathology, thyroid, salivary gland, squamous cell carcinoma, and HLA as a tumor suppressor. Outside of her academic interests, Dr. Pujadas is a fan of classical music and rock climbing. One amazing fact about Dr. Pujadas is that her mom was the model for the Barcelona 1992 Olympic medals.



Beth Raju, MD

A welcome addition to our Blood Bank is Dr. Beth Raju, who joined our department as Assistant Professor and Assistant Director of Blood Bank and Transfusion Services. Dr. Raju went to medical school at University of Oklahoma College of Medicine and stayed at University of Oklahoma for her residency. Dr. Raju then moved to the Northeast for her Fellowship in Transfusion Medicine at New York Blood Center/Weill Cornell. Her academic interests center on medical education, with a focus on improving teaching and advancing educational initiatives within and across departments. She has a strong interest in leadership development and contributing to initiatives that support academic growth and mentorship in medical education. When she's not in the Blood Bank, Dr. Raju can be spotted running, doing Pilates, and reading. Dr. Raju also wanted it known on the record that she can be bribed with chocolate cake



Matthew Shapiro, MD

Dr. Matthew Shapiro is an Assistant Professor in Hematology/Coagulation and Hematopathology. Dr. Shapiro earned his MD at St. George's University School of Medicine and completed both his residency training in Clinical Pathology and Fellowship training Hematopathology at Mount Sinai Hospital. Dr. Shapiro is Board Certified in Clinical Pathology and Hematopathology. Dr. Shapiro's expertise is in flow cytometry, hematology, coagulation, and laboratory management. When not at work, he can be found on the basketball court. He is a loving uncle to three adorable nieces and one newborn nephew!




Stephanie Shea, MD

We are incredibly happy to have Dr. Stephanie Shea return back to Mount Sinai as an Associate Professor specializing in Pediatric Pathology after she did her AP/CP residency at Mount Sinai Hospital. Before she came to Mount Sinai, Dr. Shea went to medical school at SUNY Downstate. After Mount Sinai, she moved to the Midwest for a Fellowship in Pediatric Pathology at Cincinnati Children's Hospital Medical Center. Dr. Shea is interested in studying the placenta and pediatric surgical pathology. When not working on pediatric pathology academia, Dr. Shea enjoys cooking, singing/dancing, and spending time with family. Dr. Shea is also a big travel fan and is a Disney vacation club member.



Tingting Li, PhD

Not many people can name their favorite immune cells. For Dr. Tingting Li, she can answer very easily that her favorite immune cells are $\gamma\delta$ T cells. A great new addition to our department's Research Faculty, Dr. Li joins us as Instructor of Pathology. Dr. Li did her PhD training in Peking University and, after moving to the U.S., did her Postdoc training at Weill Cornell Medicine. Dr. Li's area of research focus is on studying microbe-host interaction. When not in the lab, Dr. Li loves planting and photography.



Alive

Often and by many is the question asked,
“How are you today?”

Candid and genuine is my own morbid
response, “Alive.” The change is sudden, the
facial expression astray.

The remark is questioned with its misleading
confusion and clouded doubt.

Life and death, the codependent pair where
tensions do mount.

Granted is the life we take and temporarily
possess.

For some health remains. For others it’s the
opposite leading to physical and emotional
distress.

Anatomical deviations far from what is normal.
Medical interventions that prove we are complex
yet mortal.

Our brains, hearts, and other organ parts work
in conjunction.

Sometimes a bit too much, such as autoimmune
disorders which lead to self-destruction.
From blood in a vacutainer to a subcellular level
you can’t see.

To a family signing consent forms for their
loved one’s autopsy.

Intricate examinations through the branch of
pathology.

For this I continue to offer my response without
an apology.

Life's a journey with a turbulent drive.
Nonetheless, I’m thankful for another day I’m
alive.

- Kim Argueta, MS

Department of Pathology, Molecular and Cell-Based Medicine
1468 Madison Ave., 15th flr., Annenberg Bldg. New York, NY

Editorial Team

Dr. M. Isabel Fiel
Dr. Shafinaz Hussein
Dr. Ippolito Modica
Dr. Camelia Iancu-Rubin
Scott Goldfarb
Allan Esperida